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Up to 70% of U.S. businesses in the biotech industry received Food and Drug 
Administration (FDA) noncompliance citations in 2015. The effective implementation of 
quality management strategies may lead to improved quality compliance. The purpose of 
this qualitative multiple case study was to explore the strategies that quality compliance 
managers in biotech companies use to integrate and apply FDA product quality 
compliance requirements into their products’ quality compliance metrics. Deming’s 
strategic models for developing and implementing quality provided the conceptual 
framework for the study. The study participants consisted of five biotech quality 
compliance managers in the West region of the United States who had successfully 
implemented strategies to integrate and apply FDA product quality compliance 
requirements into their quality compliance metrics. Data were collected from 
semistructured interviews and public documents. Data were analyzed according to Yin’s 
5-step process of compiling, disassembling, interpreting, and making conclusions. Three 
themes emerged from the data analysis: product quality outcomes, policies and 
procedures, and collaborative partnerships. A key recommendation includes compliance 
managers identifying collaborative quality compliance opportunities within and outside 
their organizations. The implications for positive social changes include the availability 
of needed drugs for society. Growth in the biotech industry may improve the overall 
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Section 1: Foundation of the Study  
As the biotech industry becomes increasingly larger and faster paced, the Food 
and Drug Administration’s (FDA’s) quality regulatory regime becomes even more 
stringent (Huang et al., 2020). Improved regulatory quality compliance strategies have 
become imperative for compliance managers in the biotech industry (Huang et al., 2020). 
As Chen et al. (2019) noted, manufacturers must think about quality compliance from the 
early product development phase and should also consider FDA quality compliance 
requirements. The lack of quality compliance accounts for failing profit in the biotech 
industry (Katamesh et al., 2019). Quality compliance managers should develop quality 
compliance strategies to attain full FDA product quality compliance requirements as best 
practices (Chen et al.,2019). My focus in this qualitative multiple case study was to 
explore the strategies used by quality compliance managers in the biotech industry to 
attain full FDA product quality compliance. Identifying the strategies used in the industry 
to attain FDA product quality compliance may result in improved compliance in the 
industry, may improve industry profitability, and may reduce the number of 
noncompliance citations received in the industry. 
Background of the Problem 
Biotech firms received quadrupled FDA noncompliance citations in 2015 
(Katamesh et al., 2019). Katamesh et al. (2019) further noted that noncompliance with 
FDA product quality regulations had continued to negatively impact the industry’s 
profitability. According to Wang et al. (2016), noncompliance with the FDA’s product 
quality regulations in the biotechnology industry impacts the industry’s profitability and 
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has a negative impact on future research outcomes. The FDA reported a 64% increase in 
the amount of current Good Manufacturing Practice (cGMP) noncompliance from 2007 
to 2012 (Wang et al., 2016). Despite the development of new products in the biotech 
industry, financial growth rate was low due to an increase in associated product quality 
compliance fines and citation costs (Katamesh et al., 2019). My focus in this qualitative 
multiple case study was to explore the strategies used by biotech companies to integrate 
FDA product quality requirements into their product quality metrics.  
Problem Statement 
The slow growth rate and failing profit of U.S. biotechnology industry is tied to 
the FDA’s product quality compliance and enforcement regulations (Fox et al., 2017). 
Noncompliance with the FDA’s product quality regulation in the biotechnology industry 
impacts the industry’s profitability and has a negative impact on future research outcomes 
(Katamesh et al., 2019). The FDA reported a 64% increase in the amount of current 
cGMP noncompliance from 2007 to 2012 (Wang et al., 2016). The general business 
problem was the biotech industry is unable to incorporate FDA quality compliance 
requirements into their operational business practices despite its impact on their 
profitability. The specific business problem was some quality compliance managers in 
the biotech industry do not have the strategies to integrate and apply FDA quality 
compliance requirements into their products’ quality metrics. 
Purpose Statement 
The purpose of this qualitative multiple case study is to explore the strategies that 
quality compliance managers in biotech companies use to integrate and apply FDA 
3 
 
product quality compliance requirements into their products’ quality compliance metrics. 
The target population consisted of five biotech quality compliance managers in the West 
region of the United States who had successfully implemented strategies to integrate and 
apply FDA product quality compliance requirements into their quality compliance 
metrics. The findings of this study may contribute to social change by providing the U.S. 
population with more rapid access to urgently needed drugs and treatment. The findings 
from this study may also help to mitigate FDA citation compliance violation cost 
incurred by the biopharmaceutical industry, which is typically passed down to the public 
in the form of higher drug costs. 
Nature of the Study 
For this study, I considered three research methods: (a) quantitative, (b) 
qualitative, and (c) mixed. After considering these research methods, I chose the 
qualitative method. Qualitative methodology is appropriate for creating a deeper 
understanding of a contemporary phenomenon within a real-world context (Bernard, 
2013). According to Yin (2017), using the qualitative research method provides an 
opportunity for a better understanding of the subject of study. As Ritchie et al., (2016) 
opined, using the qualitative method provides the researcher with a naturalistic 
interpretive approach to understanding the meaning of events and phenomena. In 
contrast, the quantitative research method is used to test hypotheses about variables’ 
relationships (Jacob et al., 2015). The quantitative research method was unsuitable for 
this study’s focus on identifying and exploring the strategies used by quality compliance 
managers to integrate and apply FDA quality compliance requirements into their 
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companies’ quality metrics. Quantitative methodology was rejected because I did not 
need to examine variables’ relationships through testing a hypothesis to address my 
study’s purpose. Researchers use mixed methods when combining qualitative and 
quantitative methods in one study. I rejected the mixed-methods approach because I did 
not need to combine quantitative and qualitative methods. I used a qualitative method 
because employing a qualitative method would enable a detailed analysis of the different 
strategies used by quality compliance managers in the biotech industry to integrate and 
apply FDA quality compliance requirements into their products’ quality metrics.  
I chose a multiple case study design for this study. A case study design was 
suitable for this study because using a case study design would enable me to ask what, 
how, and why questions. Researchers use multiple case study designs to understand the 
similarities and differences between cases (Yin,2017). Baškarada (2016) argued that 
researchers use the multiple case study design to generate evidence from multiple cases, 
which makes the study more reliable. I selected a multiple case study for this study to 
clarify findings and to ensure a wider discovery of evidence to answer the research 
question. Yin (2017) argued that using case study designs enables the researcher to 
answer what, how, and why questions more effectively than any other design. In the 
current study, I wanted to identify and explore the strategies used by compliance 
managers when formulating and integrating current FDA quality compliance 
requirements into their products’ quality metrics. I considered other designs such as (a) 
narrative, (b) ethnography, and (c) phenomenology.  
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Researchers use the narrative design to explore research participants’ personal 
stories. The current study focused on business strategies and not personal stories. 
Therefore, the narrative design was unsuitable. Researchers use the ethnographic design 
to study participants’ daily lives, community processes, and activities in a defined study 
population (Small et al., 2014). Also, researchers use the ethnographic design to study 
social interaction and culture of a group of people (Hoeber & Shaw, 2017). I did not 
address any social interactions in this study; therefore, the ethnographic design was 
unsuitable. Phenomenology researchers seek to understand the meanings of participants’ 
personal experiences with a phenomenon. I rejected the phenomenological design 
because I did not focus on identifying and exploring the personal meanings of 
participants’ experience of a phenomenon. Rather, I focused on identifying and exploring 
business strategies. The multiple case study design was appropriate for this study because 
employing a case study design allowed me to effectively explore the strategies used by 
quality compliance managers to integrate and apply FDA quality compliance 
requirements into their products’ quality compliance metrics. 
Research Question 
What are the strategies use by quality compliance managers in the biotech 
industry to integrate and apply FDA quality compliance requirements into their products’ 
quality metrics? 
Interview Questions 
The following interview questions were used to answer the research question: 
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1. What leadership strategies do you use to embed a culture of quality and 
compliance within your company?  
2. How does your management team formulate and adopt product quality 
compliance techniques?  
3. How does your organization integrate quality compliance strategies into your 
internal and/or external quality compliance metric systems?  
4. What total quality management processes and tool does your organization use 
to implement your quality management strategies?  
5. How does your organization identify the key opportunities for quality 
improvement within your quality and compliance processes to ensure 
compliance with FDA quality requirements? 
6. What, if any, supply chain management technologies do your organization use 
to address key barriers to integrating FDA product quality requirements into 
your product quality metrics? 
7. What are the strategies used by your organization to monitor quality 
compliance throughout products’ life cycles? 
8. What other information can you provide about the strategies used by your 
organization to apply and integrate FDA’s quality compliance requirements 
into your products’ quality metrics? 
Conceptual Framework 
The conceptual framework governing this study is Deming’s (1986) strategic 
models for developing and implementing quality. Although Deming’s quality 
7 
 
management theories are based on prior research by Taylor and Stewart, Deming is the 
theorist responsible for four major quality implementation theories: (a) 14 points of top 
management; (b) seven deadly diseases that management must cure; (c) plan, do, study, 
act; and chain reaction quality implementation theories (Deming, 1986; Hackman & 
Wageman, 1995; Quality Council of Indiana, 2007). However, six of Deming’s 14 points 
for quality implementation were expected to closely apply to this study:  
1. create consistency of purpose for improving products and services;  
2. adopt the new philosophy;  
3. cease dependent inspection to achieve quality;  
4. improve constantly every process for planning, production, and service;  
5. adopt and institute leadership; and  
6. remove barriers that rob people of pride of workmanship, and eliminate the 
annual rating and merit system.  
Though other theorists such as Juran and Gryna (1988) favored a more structured 
approach to implementing quality control, Deming’s 14-point quality implementation 
theory applied to this study. As Munechika et al. (2016) opined, Deming’s 14-point 
quality implementation theory is appropriate for developing and implementing quality 
compliance strategies for use in mitigating costs that may arise from product quality 
failures. Deming’s 14-point quality implementation theory provided a viable and robust 
study platform to explore the strategies used by quality compliance managers in the 
biotech industry to integrate and apply FDA quality compliance requirements into their 




Biologics: These are sugars, protein, or nucleic acids or a combination of these 
substances or living entities such as cells and tissues that are produced by biotech 
methods and gene-based cutting-edge technologies (Strauss & Borenstein, 2015). 
Feedback loop: Feedback loop is the transmission pathway of cause-and-effect 
information sequence (Strauss & Borenstein, 2015). 
Good manufacturing practices: Good manufacturing practice (cGMP) refers to 
the regulated FDA rules that provide for systems that ensure proper design, monitoring, 
and quality of manufacturing processes and facilities (Hadjul & Kolinska, 2016). 
Quality strategy implementation techniques: Quality strategy implementation 
techniques are the techniques for selecting a supply chain quality implementation strategy 
(Strauss & Borenstein, 2016). 
Quality control samples: Quality control samples are the small product 
specifications used to assess the precision and accuracy of an assay and the stability of 
the samples (FDA, 2018). 
Risk mitigation: Risk mitigation is the level of exposure to organizational 
uncertainties that a leader must understand and be able to efficiently manage to create 
values without undermining organizational values (Strauss & Borenstein, 2015). 
Supplier risk metric: Supplier risk metric is a designated system of calculating 
inherent risks within a supplier that may create quality issues down the supply chain 
(Hadjul & Kolinska, 2016). 
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Supply chain quality responsiveness: Supply chain quality responsiveness is the 
promptness to which supply chain quality managers address quality issues within the 
supply chain network (Sharma et al., 2018). 
Supply chain quality risk management: Supply chain quality risk management is 
the simple but clear and concise process of creating and managing risks throughout the 
supply network (Hadjul & Kolinska, 2016). 
Assumptions, Limitations, and Delimitations 
Scholarly inquiries often address public views, perceptions, and realities through 
analysis, values, and assumptions (Denzin, 2012). Strauss and Borenstein (2015) noted 
that the procedures of qualitative studies may be imprecise in comparison to a 
quantitative study because qualitative research focuses on understanding the experiences 
and observations of the target population. Therefore, the targeted population behaviors 
and practices are drawn from assumptions. 
Assumptions 
In a research study, assumptions are statements the researcher believes to be true 
and valid though these statements may not have support (Yin, 2017). In a qualitative 
study, key assumptions may form the basis upon which the researcher begins the study 
(Yin, 2017). In the current qualitative study, I assumed that the participants would answer 
all interview questions honestly and truthfully and that the participants would honestly 
share their understanding and processes through which they form their quality 
compliance practices. I also assumed that the participants’ experiences related to quality 
compliance strategies would adequately describe the phenomenon under exploration.  
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Further, I assumed participants had experience in FDA quality compliance 
processes and could articulate their experiences related to the research problem. I 
assumed the information given was bias free. Also, I assumed the participants would 
provide information that was true and represented their actual experiences rather than 
their guesses or expectations. A qualitative researcher should always identify emerging 
themes and patterns from the data received to avoid researcher biases (Lichtman, 2017). 
These assumptions lead to certain unavoidable research limitations. 
Limitations 
A limitation is a condition or restriction preventing the state of completeness 
(Kirkwood & Price, 2017). Limitations in a study may restrain the transferability of the 
findings. Also, a lack of peer-reviewed research material may limit the efficacy of a 
research finding. Yin (2017) noted participants’ less than optimal responses and 
individual biases as a research limitation may influence the research reliability and 
validity. One limitation of the current study was the decision to use only two sites. This 
limitation could have negatively impacted the research reliability because it limited the 
number of participants who could have participated in the study. However, researchers 
introduce delimitations to effectively complete the study (Yin,2017). The researcher 
selects the research design that will accomplish the research goal and accepts limitations 
that are necessary to attain the research goal (Noble & Smith, 2015). In the current study, 




Delimitations are the research boundaries reflecting the conscious omission and 
addition of elements during development of the research plan (Marshall & Rossman, 
2016). Supply chain professionals, quality compliance managers, auditors, indirect 
suppliers, and technical leaders participated in the current study. I explored how 
organizations in the biotech industry develop and deploy their quality compliance 
strategies. The research participants had 10–20 years of experience in quality compliance 
management, corporate governance, and operations management in the West region of 
the United States. 
Significance of the Study 
The findings from the study may contribute to the current body of knowledge 
related to how biotech quality compliance managers develop and implement quality 
compliance strategies in response to FDA quality compliance requirements. Practitioners 
may use the findings in the study to fill gaps in their current quality compliance 
governance and strategies. The outcome of the study may serve as a reference guide for 
quality compliance managers in selecting a strategy for FDA quality compliance 
requirements. Quality compliance managers may use the recommendations in this study 
when responding to FDA quality compliance visitations and citations. 
Contribution to Business Practice 
An explorative analysis such as this study may provide a clear and succinct 
approach to business practice optimization such as earning quality compliance on the first 
FDA inspection visit. This study may provide practitioners with strategies for developing 
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and implementing quality compliance measures in response to FDA product quality 
requirements. Practitioners may use the outcome of this study to mitigate the cost of FDA 
product quality noncompliance enforcement. 
Implications for Social Change 
The implementation of the strategies discussed in the study may reduce drug 
shortage of urgently needed biopharmaceutical drugs. The results of the study may lead 
to growth in the U.S. economy by improving efficiencies in the biopharmaceutical 
industry. Growth in the biopharmaceutical industry may result in job creation and 
employment opportunities for Americans who work in biotech companies. 
A Review of the Professional and Academic Literature 
This literature review resulted from an exploration of peer-reviewed articles, 
government regulations, and business books that related to the research question 
addressing the strategies used by quality compliance managers in the biotech industry to 
apply FDA quality compliance requirements in their products’ quality metrics. The 
conceptual framework for the examination of the research question consisted of 
Deming’s (1986) strategic models for developing and implementing quality. 
Application to the Applied Business Problem 
There was a gap in the available literature for supply chain quality management 
strategies used by quality compliance managers in the biotech industry to attain FDA 
product quality compliance. I did not find any literature that directly addressed the 
research question. To conduct an effective review of the literature addressing the research 
topic, I extended the search to include all terms that described processes and practices 
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used by quality compliance managers in the biotech industry to formulate strategies to 
attain FDA quality compliance. Researchers used terms such as compliance metrics, 
regulatory compliance, process improvements, and monitoring to describe some 
organizational practices used by quality compliance managers in the biotech industry to 
formulate strategies in response to FDA product quality requirements (Giri & Sarker, 
2017; Halldorsson et al., 2015; Kirovska et al., 2016). The literature review covers 
compliance metrics, process improvements, and monitoring related to practices that 
describe quality compliance managers’ activities directed at FDA quality compliance 
requirements.  
 The literature review begins with an overview of Deming’s (1986) strategic 
models for developing and implementing quality as the conceptual framework of the 
study, followed by a review of contrasting and supporting quality management theories. 
The literature review continues with an analysis of the U.S. regulatory and public health 
policies. Further, I explore the FDA’s quality regulatory policy by examining the FDA’s 
cGMP. Next, I address theories, concepts, and practices relevant to the study of FDA 
quality compliance requirements: (a) quality assurance role in the biotech industry, (b) 
government policies and the complexity of the biopharmaceutical delivery systems, and 
(c) government policies and the adverse effects on the biotech product quality outcomes. 
Academic Source Utilized to Conduct the Review 
In support of this study, I reviewed a collection of peer-reviewed articles, books, 
and government reports. I obtained peer-reviewed articles by searching academic 
databases available in the Walden University library using the following search terms: 
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Porter’s value chain, Deming management theory, supply chain quality management 
techniques, biologics and quality compliance, quality process improvements, FDA quality 
compliance citations, and supply and logistics integration. The databases I used were 
Academic Search Complete, Business Source Complete, Science Direct, Life Sciences, 
Politics & Government, and Social Science Citation Index. 
Keywords, Phrases, and Terminologies 
I used the following keywords, terminologies, and phrases when searching 
reference databases for the literature review: biotech product quality compliance metrics, 
FDA product certification metrics, FDA quality compliance requirement for the biotech 
industry, supply chain management strategies in the biotech industry, FDA product recall 
requirements in the biotech industry, and quality management strategies in the biotech 
industry. 
Diversity of Literature Sources 
The research topic required the incorporation of numerous government agency 
publications, bylaws, congressional hearings, and federal legislation. There was a need to 
assess and compare government regulatory requirement documents with industry 
practices related to FDA product quality compliance requirements. Also, I reviewed 
academic and professional organizations’ viewpoints and opinions. 
Conceptual Framework: Deming’s Quality Management Theory 
In this study, I used Deming’s (1986) management theory as the conceptual 
framework for exploring the strategies quality compliance managers in the biotech 
industry use to integrate FDA product quality compliance requirements into their 
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products’ quality metrics. Deming’s quality management theory has four major quality 
implementation theories: (a) 14 points of top management; (b) seven deadly diseases that 
management must cure; (c) plan, do, study, act; and (d) chain reaction quality 
implementation theories (Deming, 1986; Hackman & Wageman, 1995; Quality Council 
of Indiana, 2007;). Six of Deming’s 14 points for quality implementation closely applied 
to this study:  
1. create consistency of purpose for improving products and services;  
2. adopt the new philosophy;  
3. cease dependent inspection to achieve quality;  
4. improve constantly every process for planning, production, and service;  
5. adopt and institute leadership; and  
6. remove barriers that rob people of pride of workmanship, and eliminate the 
annual rating and merit system.  
Munechika et al. (2016) opined that Deming’s 14-point quality implementation theory is 
appropriate for developing and implementing quality compliance strategies for use in 
mitigating costs that may arise from product quality failures. Deming’s 14-point quality 
implementation theory was appropriate to explore the quality management strategies used 
by biotech quality compliance managers to integrate and apply FDA product quality 
compliance requirements into their products’ quality metrics. 
Create Consistency of Purpose for Improving Products and Services 
Consistency of purpose as a quality improvement strategy is one of the most 
important aspects of quality improvement strategies. One of the core components of 
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Deming’s (1986) 14-point quality implementation theory is create consistency of purpose 
for improving products and services. Other quality research and implementation experts 
agreed that consistency of purpose in quality implementation is at the core of any 
process, product, or service quality implementation (Smith & Rupp, 2016). Quality 
compliance managers should develop quality management strategies that are resilient to 
maintain consistency. According to Fawcett et al. (2016), consistency in product and 
service quality implementation guidelines and strategies improves stakeholder confidence 
in the quality implementation processes. Quality improvement strategies may take 
different forms, but consistency remains an important aspect in developing a sustainable 
product and service quality. Smith and Rupp argued that consistency in the quality 
implementation strategies within the organization continuously improves product quality 
outcomes. Deming’s 14-point quality implementation theory and the core component of 
creating consistency of purpose for improving product and services quality could help 
quality compliance managers within the biotech industry create consistency in product 
and service quality implementation. Further, consistency of purpose should also form part 
of the organization’s new product quality improvement philosophy. Smith and Rupp 
noted that consistency of purpose should be a core part of the organization’s standard of 
operation and should form part of the organization’s new philosophy. 
Adopt the New Philosophy 
Organizations create and adopt a new quality philosophy to attain sustainable 
quality implementation strategies. Deming (1986) noted that organizations must move 
past the notion of seeing quality improvement as a new periodic exercise but should 
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create and adopt the new quality implementation strategies within the organization as the 
new organization’s philosophy. The adopted strategy becomes an integral part of the 
organization’s overall quality mission. The adoption of quality implementation as a new 
organizational philosophy by everyone within the organization is key to quality 
improvement within the organization (Smith & Rupp, 2016). The inability to adopt 
quality implementation as the organization’s new philosophy may impede quality 
improvement strategies. Quality improvement as a onetime effort is not sustainable and 
may be more costly in the long run (Deming, 1986). In the 14-point quality 
implementation management theory, Deming argued that failure to adopt quality 
implementation as an organizational theory creates management chaos and defects within 
the management, planning, and production processes. To avoid such failures, managers 
within the biotech industry may adopt a new philosophy of quality implementation in 
integrating FDA quality product quality compliance requirements into their products’ 
quality metrics. 
Improve Constantly Every Process for Planning, Production, and Service 
The constant improvement of processes for planning, production, and service 
aspects of Deming’s (1986) quality improvement strategies is relevant to product quality 
improvement requirements in the biotech industry. Challener (2020) stated that process 
improvement is a fundamental component of quality improvement in product 
manufacturing. Dittes et al. (2016) agreed but noted that in instances when changes 
would delay quality implementation, consistency is required, and process may not be 
improved. However, other quality implementation practitioners agreed that continuous 
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quality process improvement planning creates a quality metric that manufacturers in any 
industry can use to improve product quality requirements (Dittes et al., 2016; Vellema et 
al., 2016). The biotech industry as a manufacturing industry could use constant process 
improvements to integrate and apply full FDA product quality requirements into their 
products’ quality metrics. Standing et al. (2016) opined that continuous process 
improvement is directly connected to process and planning improvement implementation. 
The requirement for constant process and production planning may help eliminate 
manufacturing quality errors that are costly (Stoica & Brouse, 2017). 
By adopting Deming’s (1986) recommendation to improve constantly every 
process for planning, production, and services, quality compliance managers in the 
biotech industry may develop an effective quality management strategy to integrate and 
apply full FDA product quality compliance requirements into their products’ quality 
metrics. Vellema et al. (2016) argued that this aspect of Deming’s quality management 
strategy is applicable in any manufacturing or service setting. The biotech industry as a 
manufacturing industry could adopt and implement Deming’s quality implementation 
theory without dependence on inspection and certification, which is a common practice in 
the industry. 
Cease Dependent Inspection to Achieve Quality 
Though inspection is an integral part of the FDA regulatory regime, Deming’s 
(1986) 14-point quality management theory requires little or no reliance on inspection to 
achieve product or process quality. The quality implementation process is the 
engagement of an active culture of quality and process improvement without the reliance 
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on inspections (Deming, 1986). Reliance on inspection as a quality process improvement 
strategy may impede innovation and continuous improvement (Pinto & Winch, 2016). 
Reliance on inspection is discouraged to avoid creating a culture of reliance on 
inspection, which upends a philosophy and culture of quality adherence (Ferreira, 2017). 
Ferreira argued that learned organizational cultures are more effective in implementing 
practices such as quality implementation compared to practices that are dependent on 
other activities such as inspections. Further, other researchers have opined that reliance 
on inspection to achieve quality requirement may create an environment of delay, chaos, 
and lack of management response to change and process improvement requirements 
(Belschak et al., 2016; Gunia & Kim, 2016).  
Ferreira (2017) noted that dependence on inspection creates a work environment 
that hinders employee motivation. Dependence on inspection creates delay in process 
(Gunia & Kim, 2016). Ferreira further stated that quality requirement should form the 
operational structure upon which the organization’s quality philosophy is based. Also, 
Wu (2017) opined that developing a quality philosophy improves quality compliance 
within the organization. Dependence on inspection is not enough. Organizations should 
develop a philosophy of quality compliance and adopt quality leadership that ensures the 
creation of a culture of quality compliance, not reliance on inspection (Gunia & Kim, 
2016). By adopting this philosophy of compliance, the biotech industry may be able to 
adopt and institute quality compliant leadership within the industry that may help develop 
strategies to integrate and apply FDA quality compliance requirements into their 
products’ quality metrics. 
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Adopt and Institute Leadership 
To integrate and apply FDA product quality requirements into their products’ 
quality metrics, organizations in the biotech industry must set an organizational tone of 
quality that runs through the entire management structures (Wu, 2017). By adopting 
organizational leadership that is quality oriented, an organization sets a tone of quality 
implementation and improvement (Belschak et al., 2016). Further, an organization can 
implement quality changes that improve overall quality performance within the 
organization (Belschak et.al., 2016). Escoffery et al. (2018) argued that quality 
implementation starts with the organization’s leadership capability as leadership defines 
the quality metric of the organization. Whereas leadership sets the quality implementation 
mandate, Wu (2017) opined that leadership must do more than lay down the rules; they 
also must lead by example. That is one reason why Deming (1986) opined that quality 
improvement within the organization requires leadership with a quality improvement 
mindset. Quality leadership provides a roadmap for continuous quality improvement 
(Wu, 2017). Wu further noted that, organizations through adopted leadership must 
incorporate a philosophy of total quality management.  
Organizations with quality conscious leadership creates an organizational culture 
of total quality adherents (Green et al., 2012). Smith and Rupp (2016) noted that 
management commitment is required to implement total quality goals. Smith and Rupp 
argued that organizations must select quality leadership champions within the 
organization to set the pace for a culture of quality within the organization. Escofferry et 
al. (2016) argued that, to create a culture of quality, the organizations must select quality 
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champions as leaders who would set the pace for the entire organization. Goedhuys and 
Sleuwaegen (2016) agreed. Goedhuys and Sleuwaegen noted that when leadership sets 
the pace, the entire workforce gets involved and pursues quality implementation as part 
of their work commitments. Organizations within the biotech industry may integrate and 
apply full FDA product quality compliance requirements into their products’ quality 
metrics by adopting Deming’s adopt and institute leadership quality management 
strategy. Companies in the biotech industry may use this theory to set up leadership 
responsibilities to remove all instituted forms of barriers to quality implementation within 
their organizations. 
Remove Barriers That Rob People of Pride of Workmanship and Eliminate the Annual 
Rating and Merit System 
Workmanship pride is a core factor in instituting total quality management within 
an organization. Feelings of humiliation and other morale issues such as lack of 
information, work-life balance and lack of incentives create barriers to quality 
improvement within the organization (Deming, 1987). Whereas employee recognition is 
encouraged as a form of employee motivation, improperly managed employee motivation 
may create a barrier to quality improvement strategies within an organization (Fida et al., 
2016; Golparvar, 2016). Accordingly, Wu (2017) argued that quality implementation is a 
shared responsibility between management and employees. Also, Wu noted that quality 
implementation is a shared responsibility between management and employees. Other 
researchers agreed and opined that merit and recognition should be collectively shared as 
quality management is a collective responsibility. (Fida et al., 2016; Golparvar, 2016). 
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However, Harold et al., (2016) argued that individual recognition should be given 
when an employee excels in quality management commitment. Wu (2017) agreed but 
noted that recognition should not discourage but motivate the workforce. Deming’s 14-
point for quality implementation theory is supported by recent research as Deming noted 
that, for any organizational quality requirement strategy to be successful, management 
must motivate by removing barriers that robs employees of the workmanship and effort 
needed to maintain set quality standards. Management should emphasize workmanship 
pride as a core factor in instituting quality management strategies within the organization 
(Deming, 1987). Porter’s value chain theory supports this view. 
Porter’s Value Chain Model 
Deming’s quality management theory forms the conceptual framework of this 
study. However, Porter’s value chain theory aligns with Deming’s quality management 
theory. Quality compliance managers, in the biotech industry, may integrate and apply 
FDA product quality compliance requirements into their products’ quality metrics by 
adopting Porter’s value chain model. Koc and Bozdag (2017) described the identification 
of processes and activities for the purpose of improving quality as a core component of 
Porter’s value theory. Further, Porter (1985) noted that processes are all activities such as 
may include communication and customer engagement. Quality compliance managers, 
within the biotech industry, may integrate and apply FDA quality compliance 
requirements into their products’ quality compliance metrics by identifying activities and 
processes that creates product quality compliance issues within their organizations. Porter 
noted that business leaders may use his generic value model to develop strategies within 
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their own industry to gain competitive advantages by identifying activities that impede 
value creation. This means that business leaders in the biotech industry could adopt 
Porter’s value chain model to improve product quality compliance and avoid FDA quality 
noncompliance citations. Like Deming’s management theory, Porter’s value chain model 
could form the theoretical foundation for exploring the strategies used by quality 
compliance managers, in the biotech industry, to integrate and apply FDA product quality 
requirements into their products’ quality metrics. 
Porter’s value chain model may form the basis for quality improvement within the 
biotech industry. McPhee (2015) noted that Porter’s value model is used by organizations 
to create value by improving every process within the value chain. Porter’s value chain 
model has been used as the foundation for a variety of qualitative and quantitative studies 
(Cygler & Debkowska, 2015; Koc & Bozdag, 2017; McPhee, 2015). McPhee argued that 
manufacturers could use Porter’s value chain model to improve product quality by 
identifying the areas where defect exist within the myriad of manufacturing activities. By 
contrast, Cygler and Debkowska noted that, Porter’s value chain model is applicable and 
useful in the service industry. However, Koc and Bozdag deferred and argued that 
Porter’s value chain is applicable in a manufacturing business setting. Similarly, Prajogo 
et al., (2016) argued that quality practitioners could use Porter’s value model to improve 
logistical processes and create a competitive advantage. Though the conceptual 
framework of this study is based on Deming’s management theory, Porter’s value chain 




Simons’s Levers of Control Theory 
Simons’s lever of control (LOC) theory of strategic management is a supportable 
theoretical foundation for this study. Like Deming’s strategic management theory, other 
researchers identified LOC as a strategic management tool (Martyn et al., 2016). 
According to Simons (1995), LOC theory consists of four major structures: (a) belief 
systems and core value, (b) boundary systems and risk to avoid, (c) interactive control 
systems and strategic uncertainty, and (d) diagnostic control systems and critical 
performance variables. Peters (2019) noted that, the biotech industry need to mitigate the 
crisis of noncompliance with a culture of compliance. Also, in support of these LOC 
strategic variables, Peter noted that compliance managers in the biotech industry will 
attain FDA compliance by effectively managing critical quality performance measures 
within the manufacturing process. Risk avoidance is a core part of LOC’s theory of 
strategic management and could form the basis for exploring the strategies used by 
quality compliance managers, in the biotech industry, to integrate and apply FDA quality 
compliance requirements into their products’ quality metrics. Also, Simons highlighted 
the examination of control systems and critical performance variables are a core tenet of 
Simmons’s LOC strategic management theory. Peters argued that leaders in the biotech 
industry should develop FDA quality compliance strategies to manage activities that may 
create risk.  
Deming’s strategic management theory and Simons’s LOC theory could be used 
as the conceptual frameworks for this study. This is the case because, quality 
improvement forms the basis of both theories. These theories may provide insight into 
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how compliance managers, in the biotech industry, integrate and apply FDA product 
quality requirements into their products’ quality metrics. In contrast, Social Learning 
Theory may not provide an effective theoretical foundation for exploring the strategies 
used by quality compliance managers, in the biotech industry, to integrate FDA quality 
compliance requirements into their products’ quality metrics. 
Social Learning Theory 
Social learning theory (SLT) is not an appropriate conceptual framework to 
explore the strategies used by quality compliance managers in the biotech industry to 
integrate FDA quality compliance requirement into their product quality metrics. Under 
the SLT theory, human behavior is a continuous interaction between cognitive, behaviors, 
and the human environmental elements (Bandura, 1978). Accordingly, Hartmann and 
Doree (2015) argued that SLT theory means humans learn by observing others and by 
obeying environmental factors and not rules. Bandura developed the SLT theory in a 
study while researching how to cure phobias. The focus of this study is to explore 
strategies and not behaviors. The SLT theory focuses on behaviors and how humans learn 
(Horsburgh & Ippolito, 2018).  
Therefore, SLT theory is not an appropriate conceptual framework for the 
exploration of strategies used by compliance managers, in the biotech industry, to 
integrate and apply FDA quality compliance requirements into their products’ quality 
metrics. However, several researchers have applied SLT in closely related studies. Brown 
et al., (2005) used SLT theory as the conceptual framework for studying leaderships and 
leader’s ethical behavior in a manufacturing setting. The SLT concept of modeling 
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requires that people learn behavior through observation, imitation, and identification 
(Bandura, 1978). The SLT theory would be appropriate in exploring why employees look 
to managers for motivation in work-related matters (Kalshoven, van Dijk, & Boon, 
2016). Reinforcement of ethical standards and ethical decision-making are two means via 
which leaders can make an impact on employees’ moral principles (Kalshoven et al., 
2016).  
In contrast, Deming’s quality management theory provides a robust platform for 
exploring strategies used by quality compliance managers, in the biotech industry, to 
integrate and apply FDA quality compliance requirements, into their products’ quality 
metrics. One core component of Deming’s management theory is that management 
should remove barriers such as lack of information needed to formulate quality 
requirement strategies. Managers in the biotech industry may remove such barriers by 
providing employees with current and relevant regulatory information needed to 
effectively incorporate government quality requirements (Peters, 2019). 
U.S. Regulatory and Public Health Policy 
The United States’ Food and Drug Administration (FDA) is responsible for a 
large portion of the regulatory regimes that governs the US biopharmaceutical industry 
(Chabner, 2011). Biopharmaceutical policy is a sub-category of the pharmaceutical health 
policy with the responsibility of developing drug development process (Woodcock & 
Wosinka, 2013). According to Chabner, pharmaceutical policy manages the factors of use 
and delivery and qualifies the components of drug formularies which shapes the 
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biopharmaceutical industry landscape mostly through regulatory policies by the Food and 
Drug Administration (FDA). 
U.S. Food and Drug Administration 
Before 1980 the FDA acted mostly as a protectionist regulatory entity in its 
approach to drug approvals and manufacturing inspections (Pazhayattil et al., 2019). 
Before 1980 the widespread AID pandemic made the FDA aggressive in response to 
public outcry for protection from the use of unsafe and contaminated clinical products by 
drug manufacturers (Chabner, 2011). Pazhayattil et al., noted that the U.S government 
through administrative orders and other legislations supported the FDA’s protectionist 
approach however, after 1980 the FDA’s senior leadership changed its position from 
protectionism to process quality regulation. The FDA through The Center for Biologics 
Evaluation and Research (CBER) began to protect the public through responsible safety, 
purity and potency regulations of biologics and other biopharmaceutical products 
(McLaughlin & Skoglund, 2015). 
Center for Biologics Evaluation and Research 
The FDA’s Center for Biologics Evaluation and Research (CBER) is tasked with 
the responsibility of providing the US biopharmaceutical industry and the public with 
regulatory guidance to ensure the safety, purity, potency, and effectiveness of biological 
products such as blood and blood products, tissues, gene therapies, diagnosis, and the 
treatment of human diseases (FDA, 2018). Dorsey et al., (2009) noted that CBER 
research activities creates the FDA’s regulatory requirements. For instance, through 
CBER annual guidance documents, the center provides guidance to biopharmaceutical 
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manufacturers on issues that relates to product quality design, production and 
manufacturing and testing of regulated products (FDA, 2018). In July 2020 the FDA 
through CBER issues guidance on The Safe Importation Action Plan which provides 
industry practitioners with the FDA’s Food, Drug, and Cosmetic Act (“FD&C Act”) 
section 804 to authorize demonstration projects to allow importation of drugs from 
Canada. Also, in January 2020, CBER issued Human Gene Therapy for Hemophilia: 
Guide for Industry. This document provides biopharmaceutical quality practitioners with 
specific guidance on how to attain FDA quality compliance requirements for the 
manufacture of Gene Therapy products used for the treatment of any bleeding disorders 
other than hemophilia A and B, because of the unique nature of those bleeding disorders 
(Peters, 2019). The FDA regulatory compliance regime also includes guidance from the 
Center for Drug Evaluation and Research (CDER). Drugs that are not biologics are under 
the administration of CDER. 
Center for Drug Evaluation Research 
The FDA’s Center for Drug Evaluation Research (CDER) provides regulatory 
compliance requirement for the manufacture of most drugs as defined in the Food, Drug, 
and Cosmetic Act. Although, there are some biological products that are also legally 
considered drugs, these categories are covered by the Center for Biologics Evaluation and 
Research (FDA, 2018). The CDER, through the Office of Drug Security, Integrity, and 
Response (ODSIR) provides the biopharmaceutical industry with guidance on the global 
supply chain security and the minimization of consumer exposure to unsafe, ineffective 
and poor-quality drugs (FDA, 2018). Guidance from the CDER provides experts in the 
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field of drug manufacturing with clear approach to maintaining FDA quality 
requirements (Arab et al., 2017). Similarly, while discussing the role of the CDER in 
providing regulatory compliance guidance to industry, Conrad et al., (2017) noted that 
the CDER helped in providing industry with research breakthrough for therapy 
designation.  Conrad et al., noted that the CDER provides quality compliance officers 
with drug certification process guidance and compliance strategies in the 
biopharmaceutical industry in conjunction with the FDA as well as leads the FDA’s 
implementation of the Drug Supply Chain Security Act and its policies which ensures 
drug quality and risk information regarding product recalls. 
Drug Quality and Security Act 
The U.S Congress enacted the Drug Quality and Security Act of 2013 on 
November 27, 2013 with Title II of DQSA, the Drug Supply Chain Security Act 
(DSCSA) (Elliasen, 2020). Elliason pointed out that the FDA uses this Act to provide 
quality compliance managers with steps to build an electronic, interoperable systems to 
identify and trace quality component of prescription drugs in the United States. 
Manufacturers also use the Act to control quality because the Act highlights ways to 
remove counterfeit, stolen, contaminated, or otherwise harmful drugs from the 
manufacturer’s supply chain. This is a regulatory framework to help manufacturers meet 
FDA’s quality compliance requirement. According to Elona and Albert (2016), the Drug 
Supply Chain Act of 2013 will also improve detection and removal of potentially 
dangerous drugs from the drug supply chain to protect U.S. consumers.  
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However, Haeyoung (2017) argued that the DSCSA had not been successful in 
providing compliance managers in solving product quality compliance issues as it 
compounds some compliance issues such as documentation processes. Likewise, 
Dinkelaker (2016) agreed and opined that the Act provides a false sense of safety to 
consumers but does very little to help quality compliance managers meet FDA quality 
requirements. Although the DSCSA may not answer all the compliance questions for 
quality compliance managers within the biotech industry, the Act provides a useful 
guidance. As Eliasen (2020) noted, the Act provides compliance managers with a useful 
start towards FDA regulatory compliance efforts. Under the DSCSA the FDA established 
a national licensure standard for wholesale distributors and third-party logistics providers, 
and requires these entities report licensure annually to the FDA. The FDA’s quality 
regulatory regime remains a starting point for any quality compliance effort in the biotech 
industry (Eliasen, 2020). The FDA’s quality regulatory regime forms the backbone of the 
biopharmaceutical quality compliance framework. 
FDA’s Quality Regulatory Policies 
The FDA’s drug regulatory policy provides guidance, structure, and regulates the 
pharmaceutical industry (Peters, 2019). However, some researchers opined that the FDA 
is still behind in developing a proper cadence of communication (Dorsey et al., 2009; 
Kweder & Dill, 2012; Ventola, 2015). This may be the case, but not always. As Elona 
and Albert (2016) opined that the FDA positively influenced healthcare policies in the 
United States and many other countries around the world. Further, Eliasen (2020) advised 
that drug manufacturers should seek more FDA intervention than less because the FDA 
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protect lives, improve drug quality, and prevent drug shortages in the United States. 
Eliasen further argued that the FDA protects the U.S healthcare system from nations with 
little or no quality regulations such as China and India. Kweder and Dill agreed and noted 
that the FDA has come a long way, and in the process developed more regulatory 
practices that has helped to strengthen the US biopharmaceutical quality compliance 
effort. 
FDA’s Current Good Manufacturing Practices Requirements 
Product quality standards, in the biopharmaceutical industry, are set by the FDA 
using the guidelines as stipulated in the agency’s cGMPs quality guidelines. The FDA 
using the cGMPs guidelines provides manufacturers with quality standards to meet 
product quality standards in the United States (Peters, 2019). Lincoln (2012) identifies 
the need for a quality management system as set forth by the Food and Drug 
Administration (FDA) within the Code of Federal Regulations. The current Good 
Manufacturing Practices (cGMP) is set forth in the Quality Systems (QS) regulation 
under sections 520 of the Food, Drug and Cosmetics (FD&C) Act of 1938. The FD&C 
Act of 1938 gave the FDA power to administer quality requirements for food, drugs and 
devices in the United States (FDA, 2018). The cGMPs are loosely written quality 
standards that allows each organization to set, develop and implement quality systems, 
write standard operating systems, and develop organizational forms for documenting 
compliance in accordance with the cGMPs guidelines (Peters, 2019). Wiggins et al. 
(2019) noted that, the cGMPs are meant to be easy to follow common sense guidelines 
that ensures safety and effectiveness of products delivered to members of the public as 
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product end users. Other researchers agreed the cGMPs standards are easy to follow, but 
noted that, it is the product manufacturer’s responsibility to adopt the recommendations 
even when they appear to be cumbersome (Chabner, 2011; Schneppe, 2019). However, 
Pazhayattil et al. (2019) opined that some parts of the cGMPs are too rigid to adopt in 
certain manufacturing scenario.  
Although many manufacturers consider the requirements of the FDA’s cGMPs 
standards rigorous, Peters (2019) noted that other countries worldwide are beginning to 
emulate the quality management standards set forth by the FDA in the cGMP. The United 
States quality management requirements is a pace setter worldwide (Lincoln, 2012). The 
FDA’s cGMPs provides biologics product manufacturers within the biotech industry with 
details of what a qualified quality management system should comprise (Wiggins et al., 
2019). The cGMPs quality management guidelines provide manufacturers with a 
reference when designing their quality metrics, such as the proper documentation of 
processes associated with the product manufacturing procedure (Schnieppe, 2019). For 
example, if an organization fails to document a quality procedure in the manufacturing 
process, the FDA will conclude that the manufactured product is defective, adulterated 
and does not meet the FDA’s quality requirement and thereby subject to product recall, 
and in some cases, closure of the manufacturing facility (Wiggins et al.,2019). In a less 
severe instance of cGMPs quality standard non-compliance, the FDA may issue an FDA 
Form 483 listing all observations, or may issue a warning letter (Peters, 2019). 
An FDA form 483 is a report issued by the FDA to organizations in which the 
FDA documents concerns and observations for one of three reasons: (a) the organization 
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lacks proper procedures for regulated areas within the manufacturing facility, (b) 
organization has FDA approved procedures but fails to follow the procedures, or (c) 
organization lacks sufficient documentation evidencing proper implementation of 
procedure (Mirasol, 2020). Mirasol noted that he most common reason for FDA form 483 
Observations and Warning Letters in the biotech industry is the lack of quality 
compliance procedure documentation. The lack of a culture of compliance accounts for 
other FDA form 483 Observation and Warning Letter issuance in the biopharmaceutical 
industry (Mirasol, 2020). The inability, by the quality compliance department to develop 
clear and concise written procedures in conjunction with other departments such as 
collaborations with quality assurance department, production department and information 
technology department also accounts for a reasonable number of FDA citations (Peters, 
2020).  
Poor laboratory procedure is the most common recurring theme in FDA warning 
letters (Wiggins & Albanese, 2019). Wiggins and Albanese further stated that, in many 
cases, either procedure is nonexistent, or the procedures are not properly documented. 
Other reasons for FDA 483 observation and warning letters includes equipment 
mismanagement issues such as lack of inspection and cleaning records, lack of 
maintenance documentation and improper handling of final products (FDA, 2018; Peters, 
2020; Wiggins & Albanese, 2019). These research findings are relevant to this study 
because the current findings highlight the key issues faced by quality compliance 
managers in developing a strategy to attain FDA quality compliance regulatory 
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requirement within the U.S biotech industry. As noted by Wiggins et al. (2019) Quality 
assurance gives rise to a successful quality compliance in an organization. 
FDA’s Response to Biopharmaceutical Quality Compliance Failures 
The FDA has developed detailed recommendation for product quality compliance 
for the U.S biopharmaceutical industry. Kweder and Dill (2012) discussed in their 
empirical study the FDA’s response to biopharmaceutical quality issues and provides an 
analysis of the strategies adopted by the agency in developing and coordinating quality 
metrics as outlined in the revised cGMPs recommendations. The authors noted that, 
whereas the FDA has created rules developed and administered by CBER, the biotech 
industry is yet to gain all the benefits promised by the FDA. Quality failures in the 
biotech industry is cause by internal failures, not the FDA’s inability to regulate the 
industry. Peters (2019) opined that FDA guidelines are to help the biopharmaceutical 
industry and not to hinder the industry. Accordingly, Kweder and Dill noted that since the 
agency’s inception, it continued to work with drug manufacturers to avoid drug shortages 
that may result from quality failures by providing annual guidelines.  
However, Wiggins et al. (2019) concluded the FDA’s quality regulatory regime is 
beginning to look like the agency’s pre-1980 approach as manufacturers within the 
biopharmaceutical industry are unable to meet the quality compliance standards set by the 
FDA through the applications of the cGMPs guidelines. In contrast, Peters (2019) noted 
that the FDA’s cGMPs standards and recommendations are easy to follow whenever 
industry practitioners develop a metric for administering the requirements of the cGMPs. 
Quality compliance managers may efficiently adopt the cGMPs quality regulatory 
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guidelines when designing a working quality compliance metric that follows the FDA’s 
annual cGMPs guidelines. As Peters pointed out, the FDA annually improves the quality 
compliance metrics for industry practitioners. 
FDA’s Quality Improvement Process Recommendations 
The FDA quality improvement recommendations provides the biopharmaceutical 
industry with useful tools for addressing quality compliance issues such as quality 
compliance documentation processes. Quality compliance recommendation enunciated in 
the new FDA’s cGMPs standards affords quality compliance officers across the industry 
with helpful tips and recommends that quality compliance officers in the 
biopharmaceutical industry can rely on to meet regulatory product quality requirements 
by the FDA (Peters, 2019). This is one way by which quality compliance officers may 
take a more vigilant and responsive role in responding to quality issues within the 
biopharmaceutical industry. Accordingly, Chabner (2011) discussed new efforts by the 
FDA to renew and improve response to the call for inspection of new manufacturing 
facilities. However, some researchers are of the view that the FDA’s compliance 
requirement through the instrument of the cGMPs is not helpful. That is why Pazhayattil 
et al. (2019) argued that the FDA’s current practices does very little to help in providing 
industry practitioners with helpful quality compliance guidelines that practitioners could 
consider as manufacturer friendly. It is important to note that, while Pazhayattil et al is 
not alone, authors who held this view were in the minority. The view that, the FDA’s 
effort in providing regulatory guidelines that are design to help the biopharmaceutical 
industry with quality compliance requirements is in the majority. Hence Peters noted that 
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the FDA’s effort is in the right direction as the agency’s cGMPs are easy to follow and 
product manufacturers that are committed to quality compliance can effectively comply 
with the FDA’s requirement for quality in the biopharmaceutical industry. For instance, 
the FDA continue to improve quality compliance requirements by providing updated 
cGMPs guidelines for practitioners to refer to and offer monthly and weekly updates for 
steps, processes, and strategies for compliance (FDA, 2018). Also, many researchers are 
of the view that the FDA’s regulatory guidelines help manufacturers comply with quality 
standards and not to hinder manufacturing progress (Chabner, 2011; Kweder & Dill, 
2012; Peters, 2019). 
Quality Assurance Role in Product Quality Compliance in the Biotech Industry 
Quality assurance when shared across departments creates a culture of 
compliance. Joghee (2019) explains the importance of Quality Assurance in the 
development and implementation of regulatory compliance strategies by discussing the 
methods for engaging quality engineering systems to leverage and optimize product 
quality assurance within the manufacturing process. Also, recent studies showed that, 
quality assurance role in the organization, when incorporated across all departments, and 
not left only with the quality assurance department, creates a significant improvement in 
product quality outcomes (Anwar et al., 2016; Kharub, 2019). For instance, Joghee 
opined that, to create a sustainable culture of quality, organizations must develop quality 
interactions that span all areas of the organization. In the same vein, another scholar 
noted that, management must foster an engaging relationship, centered around product 
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quality compliance, with all employees and departments and not left only in the hands of 
those who implement the quality requirements (Kharub, 2019).  
To foster the inclusion of quality assurance into the quality compliance 
commitment, researchers argued that organizations who use technologies to integrate 
quality compliance requirements across departments improve product quality outcomes 
better than those who did not (Reid, Hultink, Marion, & Barczack, 2016). Organizations 
need technologies to implement data integration. Hence, Bajaj, Garg, Sethi, and Dey 
(2019) noted that, technology enhanced collaboration between quality assurance and 
quality compliance departments is inevitable to reduce quality failures. The efficient 
collaboration between departments reduce cost by avoiding duplication of quality 
compliance efforts within the organization (Baja et al., 2019). The use of technology to 
enhance collaboration between departments such as quality assurance department and 
quality compliance department is important in developing sustainable quality compliance 
strategies within the biotech industry (Vaidya, Ganapathy, & Kumar, 2019).  
The degree to which quality assurance plays an important role in ensuring 
organizational quality compliance is determined by the tone set by upper management 
within the organization (Harold, Oh, Holtz, Han, & Giacalone, 2016; Vadaya et al., 
2019). Harold et al. described environmental factors such as work cultures, work-life 
balance and the work team structures, and overall management commitment as some of 
the techniques used by management to instill a culture of quality assurance across all 
departments within an organization. Organizations create a culture of personnel 
motivation as a technique for encouraging employees to adopt a culture of quality 
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commitment within the organization. Rubin (2012) opined that, encouraging and 
motivating employees to incorporating product and process quality assurance 
requirement across the organization gives employees significant insight into the product 
being produced and the strategies employed. Motivating employees to embrace shared 
quality assurance strategies across organization improves overall quality compliance 
culture (Fida et al., 2015). In support of this view, Page et al., (2015) argued that 
organizations need employee commitment across departments to make quality 
compliance a shared responsibility across the organization. Further, when Quality 
Assurance operates without interrelations with other departments such as operations, 
production and quality compliance departments, product quality compliance risk 
increases (Fida et al., 2015). However, Rubin noted that, in some instances, Quality 
Assurance is sometimes viewed as an obstruction to production goal. Nevertheless, Page 
et al., (2015) noted that the requirement to make quality compliance a shared 
commitment within the organization is inevitable. Hence, according to Fida et al., (2015), 
management must set the organization commitment tone for quality compliance within 
the organization. 
Government Policies and the Complexity of the Biopharmaceutical Delivery 
Systems 
The complexity of the U.S biopharmaceutical delivery system impacts product 
quality compliance. McLaughlin and Skoglung (2015) noted that due to the delivery 
complexity of the U.S biopharmaceutical system, there is a lack of academic research and 
reservations within the product quality management systems as it relates to the 
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biopharmaceutical delivery systems. The limit in academic research in the 
biopharmaceutical quality management regime creates quality compliance issues which 
contributes to the delay in product development (McPhee, 2015). Munechika et al., 
(2016) argued that globalization and the popularity of biopharmaceuticals contributed to 
the complexity of the product manufacture and delivery systems. However, the FDA 
provides new guidelines with more research and to mitigate the complex product delivery 
system (FDA, 2018). However, management would develop individual practices to 
mitigate the complex delivery systems and attain full FDA product compliance 
requirements (Wang et al., 2016). The biopharmaceutical product delivery complexity 
accounts for many quality compliance failures within the industry (McPhee, 2015). 
Accordingly, Marisol (2020) discussed how the globalization and popularity of 
biopharmaceuticals creates a degree of complexity for the FDA when designing 
compliance requirements. The authors observed the inherent complexities in the 
compliance requirement systems as it relates to communication between the FDA and 
industry practitioners when developing product quality compliance requirements. In 
contrast, Wang et al. argued that, beyond global process complexity, the FDA had not 
developed a compliance requirement good enough to effectively regulate 
biopharmaceutical product complex delivery systems. The FDA should not police 
manufacturers but should continue to offer simple and attainable guidelines that U.S 
biopharmaceutical manufacturers could rely on with certainty. According to the authors, 
the government can make compliance easy by creating a local platform for U.S 
manufacturers. The authors argued that by creating a local compliance platform without 
40 
 
focus on the global market, local compliance is made easy for local U.S manufacturers. 
Also, Janvier-James (2016) concluded that the solution to compliance in the 
biopharmaceutical industry rest with the individual organizations and not the FDA’s 
regulatory regime. Wang et al. suggested using management strategies such as 
organizational changes and leadership training to implement FDA product quality 
requirements within the organization. Wu noted that, rather than using draconian 
regulatory strategies and creating increased violations and citations, the FDA could help 
improve quality compliance by utilizing a collaborative working relationship with the 
industry by developing a process of working collaboratively with the biopharmaceutical 
industry to attain and improve compliance within the United States. Though the product 
manufacture and delivery system are complex, Janvier-James concluded manufacturers 
are responsible for compliance through personnel planning and training. 
From a quality management theory perspective, McPhee (2015) theorized quality 
management strategies as enunciated by Deming (1987) may provide industry 
practitioners with the needed approach to applying and implementing quality 
requirements in a very complex product delivery setting. Harold et al. (2016) agreed and 
stated that, FDA noncompliance citation hinders the growth of the biopharmaceutical 
industry. Other researchers had opined that, the application of quality management 
strategies that relies on organizational culture of quality management will improve 
compliance and reduce chaos resulting from lack of compliance (Harold et al, 2016) 
Deming’s quality management theories applied in a complex manufacturing stetting may 
provide respite growth and reduce failures resulting from lack of quality compliance 
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(Deming, 1987). Additionally, as Janvier-James noted, organizations should train 
employees on specific government regulations and policies that impacts the 
organization’s efforts towards quality compliance. 
Government Policies and the Adverse Effects on Biotech Product Quality Outcomes 
Government quality regulatory policies, in some instances, have adverse effects 
on product quality compliance efforts in the biotech industry. Some researchers agreed 
that cumbersome and hard to follow quality regulatory policies accounts for majority of 
the lack of compliance issues in the biotech industry (Giesecke, 2000). The contrasting 
roles of the U.S Government in the development of the biotechnology industry is 
undeniable (Deng, Hu, Pray, & Jin, 2019). Further, Harold et al. (2016) noted that, in 
some cases, the FDA creates new quality compliance problems while developing 
solutions to old quality compliance problems. Whereas Janvier-James (2016) argued that 
quality compliance rests solely with the individual organization, the implication of 
government policies such as the New Drug Application (NDA) processes and the Foreign 
Investment Risk Review Modernization Act (FIRRMA) of 2018 are examples of 
government policies that may have adverse effects on product quality compliance in the 
United States (Deng et al., 2019). 
New Drug Application Policy 
The new drug application (NDA) policy is under the auspices of the Food, Drug, 
and Cosmetics Act (FD&C) of 1938. The Act required pharmaceutical companies to 
include only information relating to a proposed new drug’s safety. However, in 1962 the 
FD&C Act require pharmaceutical companies to include evidence on the new drug’s 
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effectiveness for its intended use and confirm that the new drug’s established benefits 
outweighed its known side effects. The rigorous NDA process may have a negative 
impact on drug quality compliance. Van and Pray (2019) argued that the NDA process as 
administered by the FDA’s Center for Drug Evaluation and Research (CDER) is too 
lengthy and may have a few lessons to learn from the legalization of Marijuana process 
adopted by many states in the United States. The authors argued that the CDER’s use of 
10 months to review new drug applications as only one phase of multi-steps process that 
pharmaceutical companies must navigate in order to successfully bring a new drug to the 
market is problematic. As Harold et al. (2016) opined, FDA’s policies such as the NDA 
process may negatively impact investor’s commitment and interest in the biotech 
industry. Other policies such as the Foreign Investment Risk Review Modernization Act 
(FIRRMA) directly makes the biotech industry unattractive to foreign investors. 
Foreign Investment Risk Review Modernization Act 
In August 2018, Congress passed the Foreign Investment Risk Review 
Modernization Act (FIRRMA) as part of the Fiscal 2019 National Defense Authorization 
Act. FIRRMA may have a negative impact on product quality compliance by reducing 
foreign investment in the biotech industry. FIRRMA broadened the scope and oversight 
of the Committee on Foreign Investment in the United States (CFIUS) to include the 
review of foreign investments in companies involved in critical biotech technologies 
(Westbrook, 2019). Wakely and Indolf (2018) opined that the Act has an adverse effect 
on foreign investment. The U.S government directed the Act at curbing investment in the 
biotech industry from China, but the Act invariably has an adverse impact on venture 
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capital (VC) investment in biotech. Under the FIRRM regulatory regime, foreign 
investors are required to go through rigorous application reviews which required several 
months of review time and very expensive legal fees before investing in the biotech 
industry (Wakely & Indolf, 2018). According to Leiter, Caccia, Cruz, Hoffman, Gafni, 
and Gerkin (2019), FIRRM Act may push US investors to foreign markets and create 
shortage of essential drugs in the United States. The Council of State Bioscience 
Association (CSBA) noted that, the bill could lead to a reduction in drug manufacturers’ 
revenues and may lead to a reduction of approximately eight to 15 new drugs coming to 
market (Wakely & Indorf, 2018). The Act may indirectly impact new product patents as 
biopharmaceutical patents are capital intensive projects. 
America Invents Act of 2011 
The America Invents Act (AIA) of 2011 provided the most extensive revision of 
U.S. patent law in the past 60 years and may undermine innovation (Miyagiwa, 2015). 
The Act is arguably one of the United States Patent and Trademark Office’s (USPTO) 
most extensive guideline on Patents in the United States. According to Yelderman 
(2019), the Act has too many unintended and unknowable consequences for innovators 
who rely on the patent system to fund and protect their inventions. One significant impact 
of the AIA is that it allows a party to challenge the validity of an already issued patent 
before the USPTO. In discussing this aspect of the Act, Sipe (2019) argued that the Inter 
Partes Review (IPR) and the Post-Grant Review (PGR) of the AIA have the most 
significant negative impact for the biopharmaceutical industry.  
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In contrast, other researchers opined the AIA created viable and safe patent 
regime for the biopharmaceutical industry (Lingenfelter, 2015; Reis, 2012; Trilling, 
2012). The AIA arguably protects SMEs patents from big pharmaceutical companies. 
Lingenfelter noted that, under the new guidelines, stolen patents are registrable with The 
USPTO before true owners could. Also, Sipe (2019) noted that, whereas the first-to-
invent system to the first-inventor-to-file system is one positive aspect of the Act, the Act 
in reality creates confusion and delays in certain instances when the agency and the court 
fails to determine the true owner of a patent. 
Transition  
In Section 1, the chosen research method and design for this study is the 
qualitative case study. The research population is five biotech quality compliance 
managers in the West region of the U.S. These quality compliance professionals have 15 
to 20 years of experience implementing FDA quality compliance requirements. The 
conceptual framework for this study is Deming’s quality management theory. The 
statement of the problem and study purpose is consistent with how quality compliance 
managers perceive the challenges faced when responding to FDA quality regulatory 
compliance requirements. 
In Section 2, I described: (a) the role of the researcher, (b) the population and 
sampling methods, (c) data collection and analysis techniques, (d) a description of the 
research participants, and (e) explanation of the ethical research process. Further, section 
2 contains a description of the research reliability and validity. Section 3 contains a 
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detailed presentation of the research findings. In this section, I present recommendations 
for actions as well as suggestions for future research study. 
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Section 2: The Project 
Purpose Statement 
The purpose of this qualitative multiple case study was to explore the strategies 
that quality compliance managers in biotech companies use to integrate and apply FDA 
product quality compliance requirements into their products’ quality compliance metrics. 
The target population consisted of five biotech quality compliance managers from three 
biotech companies in the West region of the United States who had successfully 
implemented strategies to integrate and apply FDA product quality compliance 
requirements into their products’ quality compliance metrics. The findings of this study 
may contribute to social change by providing the U.S. population with more rapid access 
to urgently needed drugs and treatment. The findings from this study may also help to 
mitigate FDA citation compliance violation cost incurred by the biopharmaceutical 
industry, which is typically passed down to the public in the form of higher drug costs. 
Role of the Researcher 
In a qualitative research study, the researcher is responsible for the research 
design, data collection, and data analysis (Denzin & Lincoln, 2015). According to the 
National Commission for the Protection of Human Subjects of Biomedical and 
Behavioral Research (1979), the researcher is also responsible for all ethical concerns 
that may arise in the research process. As noted in the Belmont Report (National 
Commission for the Protection of Human Subjects of Biomedical and Behavioral 
Research, 1979), the researcher should always adhere to the core principles of respect for 
persons as research participants. Doody and Noonan (2016) emphasized the importance 
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of participants’ voluntary participation and informed consent as core ethical research 
requirements. I obtained participants’ signatures in the informed consent form. Also, the 
form contained a detailed explanation of the participants’ rights to accept, reject, or 
withdraw consent at any time during the study.  
Further, it is the researcher’s responsibility to promote the research validity by 
ensuring and managing appropriate sample sizes and avoiding personal and participants’ 
bias (Yin, 2017). Yin noted that the researcher is responsible for selecting the research 
design that fits the research purpose and accurately answers the research questions. I 
obtained Walden University’s Institutional Review Board’s (IRB) approval and guidance 
before contacting research participants. I encouraged the participants to explain their 
professional views freely and adequately without any suggestions or leading questions 
that may have caused personal bias to influence participants’ answers. Researchers use 
qualitative research methods to gain deeper understanding of people’s or groups’ 
experience without the researcher’s bias (Fusch & Ness, 2017). As Marshall and 
Rossman (2016) suggested, qualitative research questions may help the researcher 
identify and manage personal biases prior to the interview. Therefore, collected data will 
reflect the views of the participants and not the researcher’s personal views, experiences, 
or expectations.  
In this qualitative multiple case study, my role as the researcher was to explore 
strategies used by quality compliance managers in the biotech industry to apply FDA 
product quality compliance requirement in their products’ quality metrics. Researchers 
use qualitative research methodology to gain deeper insight into the study topic (Yin, 
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2017). Researchers use interview protocols to seek deeper understanding of practices and 
scenarios (Jacob & Ferguson, 2015). In the current study, I used interview questions to 
understand the strategies used by quality compliance managers to apply FDA quality 
compliance requirements in their quality compliance metrics within their firms. 
Participants 
The eligibility criteria for the five quality compliance managers to participate in 
the study were as follows: (a) employed in a leadership position with a biopharmaceutical 
company in the West region of the U.S, (b) administration and development of supply 
chain management strategies for quality compliance, and (c) demonstrated 
implementation of successful quality compliance strategies in response to FDA quality 
compliance regulatory requirements. In this study, purposive sampling was used to select 
eligible participants working in the biotech industry. Purposive sampling provides the 
researcher with informed and knowledgeable study participants (Fusch & Ness, 2017). In 
the current study, quality compliance managers who had implemented quality compliance 
strategies to apply FDA quality requirements were selected as participants. 
 I established a working relationship with the research participants by sending 
emails and making phone calls when appropriate. I gained participants’ trust by 
explaining the research overview and asking whether the participants were willing to 
participate in the study. I provided my email contact information and asked the 
participants to contact me at any time if they had any questions or needed clarifications at 
any time during the study. I provided the participants with a detailed study overview such 
as the problem statement, purpose, research questions, and interview questions. 
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Further, upon IRB approval from Walden University, I asked the study 
participants to review and return a formal letter of consent to me. This letter of consent 
returned by the participants signified their interest in participating in the study through 
their own free will. I also stated in the consent form that all participants were free to 
withdraw their consent at any time during the study. Although voluntary participation 
decreases participants’ response rate, Marshall and Rossman (2016) argued that voluntary 
and willful participation decreases the pressure to fabricate responses. It is ethical to 
ensure participants participate willfully and truthfully. 
The ethical requirement to protect participants’ confidentiality is crucial to the 
study’s reliability. As Yin (2017) opined, unethical data gathering undermines the study’s 
reliability and validity. The measures to ensure ethical protection of participants’ 
confidentiality include but are not limited to (a) use of confidentiality forms, (b) 
interview process approval by executive leadership, (c) a promise to respect participants’ 
privacy and/or the company’s confidential information, and (d) approval of the study 
from the IRB (Walden University, 2015). 
Research Method and Design  
A researcher selects a research method and design that are appropriate for the 
researcher’s study goals (Morse, 2015). My goal for this study was to understand the 
strategies used by quality compliance managers in the biotech industry to integrate FDA 
quality compliance requirements into their products’ quality metrics. To attain this goal, I 




I selected qualitative methodology for this study to explore the strategies used by 
quality compliance managers to integrate FDA quality compliance requirement into their 
products’ quality metrics. Researchers use the qualitative method to explore and analyze 
perceptions and experiences of people who are involved in an activity or process (Hoeber 
& Shaw, 2017). Through the effective use of qualitative methodology, researchers gain a 
deeper understanding of why study participants make decisions (Rosenthal, 2016). In the 
current study, the qualitative method was appropriate to provide a deeper insight into the 
strategies used by quality compliance managers in the biotech industry to integrate FDA 
quality compliance requirements into their products’ quality metrics. 
By contrast, researchers use quantitative method to analyze and examine 
relationships among variables using numerical data and hypotheses (Walsh, 2015). A 
quantitative method was not ideal for the current study because I did not test a 
hypothesis. Bernard (2013) argued that the researcher must carefully consider other 
alternative research methods before selecting an appropriate research method. Ritchie et 
al., (2016) stated that quantitative or mixed-methods approaches are not appropriate for 
studies that probe the study participants’ underlying decision-making process. In the 
current study, I intended to probe the participants’ underlying decision-making process: 
therefore, the quantitative or mixed-methods approach would have been inappropriate. 
Research Design 
The primary function of a research design is to ensure that the evidence gathered 
by the researcher can be used to effectively answer the research questions. Qualitative 
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researchers use the research design to ensure research reliability and validity (Noble & 
Smith, 2015). I selected a case study design for this study. Researchers use the case study 
design to gain a deeper understanding of the study subject (Fusch & Ness, 2015). Yin 
(2017) argued that researchers use the case study design to preserve the universal and 
evocative characteristics of a real-life event. I selected a case study design for this study 
because I intended to present the realities described by participants.  
Other qualitative designs did not support the explorative nature of this study. The 
phenomenological design would have allowed the collection of interview data for this 
study, but the phenomenological design would not have allowed the collection of 
publicly available data from multiple sources; therefore, the phenomenological design 
was not appropriate for this study. Researchers use the ethnographic design when 
examining beliefs and behaviors of culture-sharing groups (Marshall & Rossman, 2016). 
I did not select the ethnographic design for this study because I did not examine cultures 
and behaviors. The ethnographic design was inappropriate to explore the strategies used 
by quality compliance managers to integrate FDA quality compliance requirements into 
their products’ quality metrics. 
Population and Sampling 
Sampling addresses the number of participants, the number of contacts with each 
participant, and the length of time spent with each participant (Marshall & Rossman, 
2016). Purposeful sampling is used to identify and select cases related to the research 
phenomenon in a qualitative study (Fusch & Ness, 2017). The sampling of research 
participants involves affirmation that each participant meets the selection criteria 
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(Marshall & Rossman, 2016). Purposive sampling is suitable in studies in which the 
researcher seeks participants with the best knowledge concerning the research topic (Yin, 
2017). I used purposeful sampling in this study in the selection and engagement of the 
study participants. 
I used Zoom interviews to collect data. Interviewees were the primary source of 
data for this study. As Yin (2017) noted, well-informed participants with the appropriate 
knowledge can add important and needed data to the study. Unlike in a quantitative study 
where researchers choose random sampling to obtain reliable inferential results, 
qualitative researchers use a nonprobabilistic approach to choose the sample. In the 
current study, I used purposeful nonrandom sampling to choose five study participants. 
Robinson (2014) referred to purposive sampling strategies as a nonrandom selection of 
participants as part of a final group based on the uniqueness of the knowledge that they 
possess. I used purposive sampling to select participants with proven experience and 
knowledge of FDA quality compliance requirements. 
The researcher may not set an exact number of research participants; however, an 
initial range is necessary to establish effective research planning (Robinson, 2014). For 
instance, Marshall et al. (2013) interviewed 83 participants and concluded that the 
minimum number of cases in a multiple case study was two while the median was five. 
Further, Marshall et al. noted that the minimum number of interviews was 10 while the 
median was 39. In the current study, I interviewed five participants with knowledge and 
experience in addressing FDA quality compliance requirements. I collected data from 
five experienced quality compliance managers until data saturation was reached. Data 
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saturation occurs when exploring a problem under study offers no new or additional 
themes (Fusch & Ness, 2017). This selected population was enough to provide a robust 
understanding of the strategies used by biotech quality compliance managers to integrate 
and apply FDA quality compliance requirements into their products’ quality metrics.  
The specific population consisted of five quality compliance managers from two 
biotech companies in the West region of the United States who had experience applying 
and integrating FDA quality compliance requirements in their products’ quality metrics. I 
conducted the interviews in a quiet and conducive environment. As Cahyadi and 
Prananto (2015) opined, an interview should take place in a quiet location free from 
distractions with little or no noise. Further, Cahyadi and Prananto suggested that a place 
suitable for audio recording is ideal for a study interview. Also, the researcher should ask 
the participants to choose the location and time of the interviews (Yin, 2017). Yin further 
noted that a good rapport before the interview is crucial to a successful interview because 
good rapport reduces the participant’s discomfort, which can yield better answers to the 
interview questions. Based on these recommendations, I asked the participants to select 
an interview date, time, and location that was most suitable for them. I developed good 
rapport by asking about their day and other unrelated questions before the interview 
questions. 
Ethical Research 
Walden University’s IRB procedures were used as a guide for this study. Walden 
University’s IRB requires that each study participant receives an informed consent form 
that identifies the (a) purpose of the study, (b) researcher’s responsibilities, (c) procedures 
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for ensuring confidentiality, and (d) participant’s role (Walden University, 2015). 
Obtaining participants’ informed consent is a core component of ethical research 
(Gaikwad, 2017). I obtained participants’ consent to participate in this study by sending 
an informed consent form and a consent procedure letter via email to study participants. 
The procedure letter outlined the background and procedural information about the study. 
The procedure agreement included a clear and concise description of the study topic, 
sample interview questions, and participants’ expectations regarding compensation or any 
other form of reward for participating. The consent form stated that the benefit of the 
study was to the public, and for participating participants would get a copy of the 
completed study if they chose to.  
After I determined that participants had met the selection criteria, the research 
participants received an invitation to participate email from me. Upon returning the email 
communicating an interest to participate in the study, participants received another email 
with the consent form attached. The informed consent form contained information about 
the strict ethical compliance of the study, such as participants’ ability to withdraw their 
consent at any time during their participation. Participants were free to withdraw their 
consent to participate by sending an email to me stating that they did not want to 
participate any longer. Participants did not need to provide reasons why they were 
withdrawing their consent to participate. The consent form, which the participants were 
required to return before participating, ensured participants that their privacy and the 
privacy of their organization would be a priority. This study was conducted using 
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Walden’s ethical research procedures and the standard guidelines for qualitative research 
involving human subjects. 
Strict adherence to ethical guidelines is an important aspect of qualitative research 
involving human subjects (Robinson, 2014). The research in this study is conducted in 
accordance with the recommendations in the Belmont report of 1979 which is the 
acceptable minimum standard for conducting research involving human research 
participants (U.S Department of Health and Human Services, 1979). I followed the 
recommendations contained in the Belmont report to ensure the adequate protection of 
this study participants. This research was conducted after approval and an approval 
number was received from Walden University’s IRB. The approval number from the IRB 
for this study is 09-22-20-0660779. The study reports are protected using generic names. 
I did not use the actual names and location of any research participants and their 
organization. The research study data are stored on a password protected computer with 
codes and generic names. I stored all study related documents in a password protected 
thumb drive. I will store the password protected thumb drive in a locked safe for five 
years. 
Data Collection Instruments 
The researcher assumes the primary role of data collection and as such, the 
researcher is the primary data collection instrument in a case study (Gaikwad, 2017; Yin, 
2017). The use of semistructured interviews and probes contribute to the validity and 
reliability of a qualitative study (Morse, 2016; Yin, 2017). In this qualitative case study, I 
collected data from review of public documents, news releases, website information, and 
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conducted face-to-face semistructured interviews. I interviewed individuals in 
biopharmaceutical quality compliance leadership positions in three biotech companies in 
West region of the United States. The study participants were responsible for the design, 
management and administration of supply chain management strategies used in their 
respective organizations to attain and apply FDA quality compliance requirements into 
their products’ quality metrics. Marshall and Rossman (2016) opined that data 
triangulation of multiple sources is used to give credibility to a research outcome. Yin 
further noted that, case study researchers could use effective data triangulation by 
collecting pertinent information from multiple sources to corroborate the same 
phenomenon and ensure the overall study quality. 
Data Collection Technique 
I collected data via semistructured interviews, and the review of strategies used by 
quality compliance managers to integrate FDA product quality compliance requirements 
into their product quality metrics. In semistructured interviews, the researcher uses a set 
of open-ended questions combined with probes to explore participant responses 
(Rosenthal, 2016). Qualitative researchers should follow an interview protocol to conduct 
all interviews in a consistent manner and collect data from more than one source to 
achieve triangulation (Morse, 2016). In this study, I followed a semistructured interview 
protocol that would use open-ended questions combined with probes to explore the 
strategies used by quality compliance managers in the biotech industry to attain full FDA 
quality compliance requirements. I used interview protocols that contained steps for 
conducting a research interview, discussion of member checking, and explanation of 
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strategies. By following this semistructured interview and document review protocols, I 
was able to explore the strategies used by quality compliance managers in the biotech 
industry to integrate FDA quality compliance requirements into their products’ quality 
metrics. 
There are some disadvantages as well as advantages to collecting case study data 
in a semi structured interviews and in reviewing company data and documents. One of 
the advantages of collecting data through a semistructured interview is that the open-
ended questions may prompt the study participants to answer questions as well as provide 
additional perspectives gained through experience (Rosenthal, 2017). Additionally, 
probing questions may be used to clarify information as well as create and explore a 
recurring theme (Gaikwad, 2017). The use of probing questions and review of company’s 
data and documents may contribute to the research reliability and validity (Fusch & Ness, 
2016). The advantage of these open-ended research questions listed in Section 1 and the 
review of relevant company documents will enable me to explore the strategies used by 
quality compliance managers in the biotech industry to attain full FDA quality 
compliance requirements. 
One of the disadvantages of collecting data through a semistructured interview 
and the review of company data and documents is the amount of time involved in 
completing the process and analyzing the documents. Semistructured interviews and 
document reviews are time consuming and may create project creep in the research 
process (Rosenthal, 2017). As Gaikwad (2017) noted, the researcher should include an 
adequate time to complete these required steps: (a) scheduling and conducting interviews, 
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(b) document reviews, (c) transcription, and (d) member checking. To mitigate this 
disadvantage, I asked study participants to reserve an hour to review a summary of the 
interview for accuracy and to provide any additional information if needed. Therefore, 
time constraint would not impede the success of exploring the strategies used by quality 
compliance managers in the biotech industry to integrate FDA product quality 
compliance requirements into their product quality metrics. 
Data Organization Technique 
I organized the research data by creating and maintaining an electronic data logs 
on a password-protected computer. The researcher should categorize collected data and 
store the data in a safe and secure format with easy to retrieve capability (Baskarada, 
2016). The entries in the log that I created included data information such as (a) the data 
type, (b) data identifier, (c) date of collection, (d) place of collection, and (e) 
corresponding research notes identifier. I recorded notes during the interviews. Microsoft 
Excel and NVivo are the standard tools used by qualitative researchers for data collection 
and organization, data analysis and data reporting (Bree & Gallagher, 2016; Robins & 
Eisen, 2017). I collected data such as the consent form, audio recording, or transcription. 
I used a secured easy to retrieve Microsoft Excel and Microsoft Word interface to 
organize and secure collected research data. 
To keep collected data secure and organized, I created and labelled folders for 
each research participant. I used alphanumeric codes for each folder labels. I labelled 
audio recordings, consent forms and interview transcriptions with alphanumeric 
participants’ code (e.g., P3 Consent Form) and stored it in the participant’s folder. To 
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effectively analyze collected data such as interview transcriptions, I copied the 
transcribed interview data into an excel spreadsheet with appropriate headings (e.g., 
document code, participant code, question number, and responses).  
I stored electronic data gathered for this study in a password protected laptop. I 
stored physical data in a locked safe. I stored all electronic data in a password protected 
thumb drive and delete all electronic data from my laptop after the study is completed. I 
will store the thumb drive and the physical data in a safe for 5 years. Afterwards, I will 
delete the electronic data from the thumb drive, and I will shred the physical data. 
Data Analysis 
In qualitative research studies, researchers analyze and gather data during 
interviews to identify emerging themes (St. Pierre & Jackson, 2017). In this study, I 
identified emerging themes through methodological data triangulation by (a) interviewed 
qualified and experienced quality compliance managers with more than 15 years of 
quality management experience within the biotech industry, (b) interviewed FDA 
regulatory compliance officers, and (c) reviewed quality compliance documents used to 
attain FDA quality compliance requirements by the biotech industry. The use of multiple 
data sources provides researchers with a comprehensive knowledge of a researched 
phenomenon while applying methodological data triangulation (Carter, Bryant-Lukosius, 
DiCenso, Blythe, & Neville, 2016; Joslin & Muller, 2017).  
Qualitative researchers analyze data to discover themes that can answer their 
research question (Yin, 2017). In this study, the objective of the data analysis was to 
discover the strategies used by quality compliance managers in the biotech industry to 
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attain FDA quality compliance requirements. Defining the process and tools used for data 
analysis is an important step in the research planning phase in a case study (Rosenthal, 
2017). As Hoeber and Shaw (2017) noted, methodological triangulation requires the use 
of more than one method to gather data. The documents review will include published 
FDA regulatory documents, organizations compliance documents and the responses to 
developed open-ended interview questions and other company documents such as FDA 
citation letters. Themes discovered during these data analysis provided the framework for 
addressing this study research question. I used more than one data sources such as coding 
and thematic data analysis.  
Yin (2017) recommended five stages of data analysis: (a) compiling, (b) 
disassembling, (c) reassembling, (d) interpreting, and (e) drawing conclusions. Yin 
further noted that compiling data refers to the process of collecting and organizing data. 
Disassembling and reassembling include separating data and organizing data into groups 
and identifying data patterns and or themes. Interpreting data involves associating the 
emerging themes with existing research and the conceptual framework (Yin, 2017). I 
used Microsoft Word and Excel functions to gather data, disassemble, and reassemble 
interview data into meaningful themes. According to Ose (2016), the standard Microsoft 
Office program comes equipped with functionality ideal for organizing and coding 
qualitative research data. Whereas some researchers disregard Microsoft Excel as a viable 
means of organizing and coding qualitative research data (De Felice & Janesick, 2016), 
Moylan et al. (2016) opined Microsoft Office programs are the most viable, cheaper 
alternative to expensive data analysis programs for qualitative research.  
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Per Yin’s (2017) data analysis methodology, the next step was to interpret the 
themes and their meaning. I compiled collected data from interviews and company 
documents and identified emerging themes through the interactive process of disassembly 
and reassembly. As I defined emerging themes, I related the themes to supply chain 
management strategies for attaining FDA product quality compliance information in the 
literature review, Deming’s quality management theory, and newly published FDA rules 
and other related scholarly articles. Based on these data triangulation and interpretation, I 
drew and reported my research conclusions. 
Reliability and Validity 
Research reliability and validity refers to the research quality and result of the 
research outcome (Gaikwad, 2017). Research reliability and validity are related with the 
research dependability, transferability, and credibility (Morse, 2015). Fusch and Ness 
(2015) noted that, when conducting a qualitative research study, the researcher should 
adopt research techniques that contribute to the research reliability and validity. 
Qualitative researchers use four model criteria to ensure research data trustworthiness. 
The model’s four aspects are: (a) credibility, (b) dependability, (c) confirmability, and (d) 
transferability (Cope, 2015; Morse 2015). 
Reliability 
Research reliability in a qualitative research study is analogous to the research’s 
dependability (Gaikwad, 2017). Dependability refers to the reliability of the research data 
over time and in a different context (Cope, 2015; Morse, 2015). Qualitative researchers 
use different methods and strategies to attain dependability. Qualitative researchers use 
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member checking and case study protocols to solidify research findings (Cope, 2015). 
Fusch and Ness (2015) noted that, interview protocols and member checking increase the 
levels of data reliability obtained from research participants. Researchers engage study 
participants in the member checking process through semistructured interviews by which 
participants review data provided by the member for accuracy and authenticity in 
comparison to similar data from the same or other sources (Cope, 2015). Researchers link 
reliability and confirmability through similar means (Morse, 2015). 
Confirmability refers to the objectivity of the research and the absence of personal 
bias in the study (Cope, 2015). According to Morse (2015), the study findings must be 
firmly rooted in participants’ data without any part of the data invented by the researcher 
or influenced by personal bias. In this study, confirmability will occur through member 
checking, data interpretation and participants’ interview summary reviews. In addition to 
member checking of data interpretation and transcript reviews, I will use reflective 
journals to create an audit trail of findings. Reflective journals represent a remarkable 
tool used by qualitative researchers to document research observations, analytical 
findings, and emerging themes (Young & MacPhail, 2016).  
In this study, to ensure reliability, I utilized interview protocols, member 
checking, and reflective journaling. I conducted each interview using the same interview 
protocol (Appendix D) to ensure the same data collection method throughout the research 
data collection process. I used the same interview questions and the same interview 
protocols for all research participants. After each interview, I sent the same interview 
synthesis and interview summary to all the participants to validate my interpretation of 
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their given interviews and data. As Harvey (2016) noted, member checking gives the 
interviewee the opportunity to confirm the accuracy of the researcher’s depiction of their 
experiences. I used a reflective journal to document all my observations throughout the 
interviews and data review in order to gain insights on emerging themes. 
Validity 
Qualitative research quality is dependent on the qualitative researcher’s focus on 
key means of study validity (Marshall & Rossman, 2016). Accordingly, qualitative 
researchers ensure the validity of their research using credible procedures (Denzin & 
Lincoln, 2015; Marshall & Rossman, 2016). Qualitative researchers assess research 
trustworthiness by adopting the model by Lincoln and Guba which considers: (a) 
credibility, (b), dependability, (c) confirmability, and transferability (Cope, 2015; Morse, 
2015). Qualitative researchers use data triangulation and member checking to gain 
research internal validity (Berger, 2016). Credibility refers to a qualitative research 
internal validity whereas transferability refers to external validity (Morse, 2015). 
Transferability refers to the extent to which other researchers can replicate the 
study in a different context and would get the same results (Elo et al., 2016). 
Transferability describes the participants and data selection and gathering processes in a 
manner that, other researchers can replicate the processes in a different context and will 
get the same result (Morse, 2015). Confirmability is the degree of objectivity of the 
research and the absence of any personal bias on the part of the research participants 
(Cope, 2015). Research credibility refers to the truth, testability, and authenticity of the 
research data in a qualitative case study whereas dependability refers to the ability of 
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other scholars to rely on the research outcome (Morse, 2015). Data saturation ensures 
dependability and research validity (Cope, 2015). 
Data saturation occurs at the point at which no further new information or theme 
is emerging (Fursh & Ness, 2017; Houghton et al., 2015). Researchers reach data 
saturation through data triangulation and member checking as well as participants’ 
transcript reviews (Houghton et al., 2015) Abma and Stake (2016) identified member 
checking as a reliable mean to reach data saturation. 
In this study, I attained data transferability by ensuring data validity and 
authenticity through member checking and multiple source reviews of collected data. I 
compared published FDA regulatory documents with data collected from participants to 
ensure currency and reusability by future scholars. I provided detailed descriptions of the 
study context so that future readers can determine for themselves the level of the 
applicability of the study in their future selected context. I ensured credibility through 
member checking, participants’ transcript reviews and data triangulation. I interviewed 
only participants with 15 to 20 years of experiences attaining FDA quality compliance 
requirements in a nationally recognized biotechnology firm. I made participants review 
my synthetization of their documents and interview summary for accuracy and true 
depiction of their highlighted strategies use to integrate FDA quality compliance 
regulatory requirements into their product quality metrics. I addressed confirmability by 
member checking, participants’ interview transcript reviews and data triangulation to 
ensure personal bias do not form part of the data synthesizing. 
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Data saturation is an important aspect of the qualitative research study (Fursch & 
Ness, 2017). According to Abma and Stake (2016), the researcher reaches data saturation 
when no new information or theme is emerging. I attained data saturation by a 
methodological data triangulation through giving interviewees the opportunity to provide 
additional and new information. This study data saturation was reached when no new 
information or theme is emerging from additional information and documents. 
Transition and Summary 
In section 1, the chosen research method and design for this study is the 
qualitative case study. The research population is five biotech quality compliance 
managers from biotech firms in the West region of the U.S. The participants have 
designed and implemented quality compliance strategies to attain FDA product quality 
compliance. The conceptual framework governing this research study is Deming’s 
strategic models for developing and implementing quality (Deming, 1986). The statement 
of the problem and study purpose is consistent with how quality compliance managers 
perceive the challenges faced when responding to FDA quality regulatory compliance 
requirements. 
In section 2, I described: (a) the role of the researcher, (b) the population and 
sampling methods, (c) data collection and analysis techniques, (d) a description of the 
research participants, and (e) explanation of the ethical research process. Further, section 
2 contains a description of the research reliability and validity. Section 3 contains a 
detailed presentation of the research findings. In this section I present recommendations 
for actions as well as suggestions for future research study. 
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Section 3: Application to Professional Practice and Implications for Change 
Introduction 
This section includes the presentation of findings gathered from semistructured 
interviews with product quality compliance managers in the U.S. biotechnology industry 
with more than 15 years of FDA quality compliance implementation experiences within 
their selected organizations. This section also contains the application to professional 
practice, implications for social change, and recommendations for action. The section 
concludes with recommendations for further research, a reflection on my experience, and 
a summary of the study. 
Presentation of the Findings 
The purpose of this qualitative multiple case study is to explore the strategies used 
by quality compliance managers in the biotech industry to integrate FDA product quality 
compliance requirements into their products’ quality metrics. Deming’s (1986) 
management theory is the conceptual framework for this study. Using purposeful 
sampling and semistructured interviews, I interviewed five quality compliance managers 
with 15 or more years of experience implementing FDA product quality compliance 
requirements within the biotech industry in the West region of the U.S. The interviews 
were conducted via Zoom and were recorded, transcribed, and coded by using red text to 
identify themes. NVivo 12 software was used to establish significance, codes, and 
phrases among data sources. The analysis of the interview transcripts resulted in the 
identification of 42 codes and 300 meaningful quotes and phrases that supported the 
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identification of emerging themes. The emerging themes confirmed the study’s 
underlying conceptual framework.  
Three themes emerged from my analysis of the aggregation of the codes, phrases, 
and terms that summarized the strategies used by quality compliance managers to attain 
FDA product quality compliance requirements (see Table 1). The three themes were (a) 
product quality outcomes, (b) policies and procedures, and (c) collaborative partnerships. 
The three themes supported the conceptual framework of Deming (1986) and aligned 
with the research topic of the strategies used by quality compliance managers to attain 
FDA product quality compliance. The alignment of the emerging themes is seen in 
current peer-reviewed studies such as Anwar et al. (2016) and Mirza and Ahsan (2020) 
who noted that defining quality outcomes and determining required collaborative 
partnerships are key to product quality management. 
Table 1 
 
Cluster Related to the Three Emerging Themes 





P1 38 84 6 
P2 60 123 24 
P3 21 56 9 
P4 27 37 13 
P5 33 55 19 
Total 179 155 71 
 
Emergent Theme 1: Product Quality Outcomes 
The first theme of the study indicated the strategic processes used by quality 
compliance professionals to define product quality outcomes that are used in the industry 
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to attain FDA product quality compliance. The participants identified the efficacy of 
clear, simple, and easy-to-follow product quality outcomes as a strategic requirement for 
attaining FDA product quality compliance. This theme was highlighted by all participants 
and was recorded in my notes. In creating a strategy for attaining expected quality 
outcomes, participants identified three strategic methods, practices, and rules adopted 
across the industry. Table 2 depicts the response frequencies for highly summarized 
strategies in Emerging Theme 1. 
Table 2 
 
Theme 1: Product Quality Outcomes 






Product quality 5 3 179 
 
All five participants identified a clearly defined product quality outcome as one of 
the primary requirements for creating a product outcome that meets an FDA product 
quality requirement. P1 noted that “the organization must design a clearly defined 
product quality outcome that all employees involved in the quality process should 
understand and adhere to.” Further, in describing product quality outcome as a key 





Subthemes Related to Emerging Theme 1 of Product Quality Outcomes 




Training P3, P4, P5 4 25 
Buy-in P1, P2, P3, P4, 
P5, P6 
5 60 




Employee training is required to attain intended product quality outcomes. As a 
corollary, Participant 4 stated that “employee training and commitment is the first port of 
call in the pursuit of product quality compliance requirements.” Participant 2 stated that  
it should be emphasized that, only the employees who display understanding and 
mastery of the product quality outcome who should be allowed to be a part of the 
quality compliance team to develop a product that complies with FDA quality 
regulatory requirements. 
Participants 3, 4, and 5 agreed. Participant 4 went further and stated that “regular quality 
compliance training and verification of understanding is required to earn expected 
product quality outcomes.” Participant 3 also noted that “in any organization where 
employees involved in product quality compliance don’t understand the product quality 
compliance requirements, FDA quality compliance citation increases in that 
organization.” Anwar et al. (2016) opined that consistent verification of employee 
competencies is required to maintain product quality outcomes. 
Employee and management buy-in emerged as a subtheme of Theme 1. Employee 
trainings and total buy-in are fundamental requirements in defining product quality 
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outcomes (Mirza & Ahsan, 2020). Participant 5 stated that “employees must sign some 
form of documents stating that they understood the product quality requirement and that 
they support the processes.” Jagsi et al. (2014) argued that training alone is not enough 
practice to earn total quality management credits within the organization. Jagsi et al.  
noted that confirmed employee buy-in is required at every level of the organizational 
quality compliance campaign. Participant 5 noted that buy-in gives the employees the 
opportunity to state their concerns should there be any. Discussing the effectiveness of 
employee buy-in, Participant 5 further stated that “it’s a continuous learning and 
relearning process.”  Deming (1986) argued that quality management within an 
organization requires consistent management commitment to employee buy-in.  
All participants further opined that, to create a quality product outcome, 
organizations should implement a step-by-step quality outcome measurement and 
verification process using confirmable technological systems. Participant 5 noted that, 
whereas employee training is required, management are expected to put in place “a 
system to verify full and total quality management systems requirement and adherence by 
employee.” Bajaj et al., (2019) noted that providing compliance and adherence incentives 
such as training and performance feedback could help employees follow a step-by-step 
compliance verification requirement within the product quality compliance department. 
According to Rijsbergen et al. (2016), though management trust employees to comply, 
the need to track, verify, and improve product quality compliance should be routine 
within the quality management department. Participant 5 noted that “the compliance 
documentation and verification requirement is a key requirement.” All study participants 
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noted that the creation of a well-defined product quality outcome is made possible by 
engaging in step-by-step recorded employee participation and adherence to the assigned 
product quality. 
Product quality outcomes should be defined and clearly outlined. Deming (1986) 
noted that quality management theory recommends that quality outcomes are clearly 
defined as part of the product management processes in an organization. Also, 
Rijsbergent et al. (2016) opined that defining the quality outcome from the onset is an 
established product quality management technique. All current participants agreed. 
Participant 3 stated that “understanding of the quality outcomes is the first place to start, 
and management must ensure all quality management participants understand the product 
quality outcomes.” Deming (1986) argued that organizations must define quality 
outcomes and help employees understand the outcomes by providing the guidance 
needed to attain outlined outcomes. 
Emergent Theme 2: Policies and Procedures 
The second theme that emerged was the importance of organizational product 
quality policies and procedures. All five participants identified organizational policies 
and procedures as an integral part of product quality compliance outcomes. Table 4 
reflects Theme 2 that emerged from the analysis of the five participant transcripts and 





Theme 2: Policies and Procedures 








5 12 155 
 
All participants noted that organizational policies set the tone for product quality 
compliance. Participants 3 and 4 noted that, beyond organizationally stated policies for 
compliance, defined compliance procedures are vital. Participant 1 stated that “the FDA 
has clearly defined compliance policies, but most of these policies are recommendations. 
The individual organization is expected to design their own internal policies to reflect and 
follow the FDA guidance and compliance policies.” Participant 3 further noted that 
corporate policies and procedures form the basis of quality compliance: “every 
organization must signal a culture of compliance by establishing a clear quality 
compliance policy within the organization.” Martyn et al. (2016) stated that policies and 
procures are organizations’ strategies that create a culture within an organization. 
Organizations design and implement corporate strategies to implement intended 
corporate outcomes (Pinto & Winch, 2016). The implementation of corporate policies 
and procedures such as quality compliance procedures within an organization needs to be 
clearly defined (Alqahtani, 2016). In describing policies and procedures as a recurring 
theme, several subthemes emerged. Table 5 highlights the different subthemes mentioned 





Subthemes Related to Emerging Theme 2 of Policies and Procedures 






P1, P5 4 10 
Accountability P1, P2, P3, P4, 
P5 
5 30 





P5, P4, P3 1 5 
 
The core aspect of this theme aligned with the conceptual framework of this 
study, Deming’s (1986) quality management theory. Deming argued that quality 
management in a production process accentuates an organization’s competitiveness and 
sustainability, and organizations should make such quality notions part of their overall 
policies and procedures. In practice, the strategic use of policies and procedures to attain 
product quality and overall organizational effectiveness is an indispensable aspect of 
product quality implementation (Alqahtani, 2016). 
Emergent Theme 3: Collaborative Partnerships 
The third theme that emerged from this study was collaborative partnership. All 
participants identified collaborative partnership within and outside the organization as a 
key requirement for product quality compliance (see Table 6). Participant 1 noted that 
“organizations, in order to attain FDA product quality compliance requirements, must 





Theme 3: Collaborative Partnerships 








5 9 71 
 
Participant 2 argued that the requirement to comply with regulatory quality 
compliance starts with management and frontline employees. Participant 2 argued that 
“management must understand frontline needs and requirement and put on a 
collaborative hat to fully attain FDA product quality requirement.” Further, Participant 5 
noted that “companies who want to attain compliance and avoid huge violation penalties 
must partner with external agents and experts to provide compliance training.” Participant 
1 noted that “every department within the organization must collaborate on the need to 
attain product quality compliance to attain full FDA product quality compliance.” 
Further, Participant 4 stated that “collaborative partnership is required throughout the 
product life cycle.” All participants agreed that FDA product quality compliance requires 
internal and external collaborative partnerships. Participant 3 noted that “quality 
compliance is an all-hands-on-deck requirement, from product conception to product 
end-users.” Hernández‐Carrión et al. (2017) noted that organizations thrive when they 
have a successful partnership within and outside their organizations. In identifying 





Subthemes Related to Emerging Theme 3 of Collaborative Partnerships 






P1, P5 4 10 
External 
partnerships 
P1, P2, P3, P4, 
P5 
5 30 




The improve-every-process aspect of Deming’s (1986) quality management 
theory aligned with the collaborative partnerships theme of the current study. According 
to Deming, organizations must partner and collaborate with every process of the product 
or services for a single goal of product quality improvement. Participant 1 noted that 
“quality compliance managers must partner with external participants to attain product 
quality improvement.” Also, Fawcett et al., (2016) suggested that better product 
improvement success rate occurs within the organization and desired quality outcome is 
attained through collaborative participation across all spectrums. Deming’s product 
quality management theory was an appropriate framework for monitoring and engaging 
multiple participants within a product quality outcome effort. When engaging employees 
to attain product quality within an organization, leadership can use Deming’s quality 
management theory to assist in this process. 
Applications to Professional Practice 
The result of this study provided strategies that quality compliance managers in 
the biotech industry can apply to obtain FDA product compliance requirements. 
76 
 
Compliance managers in the biotech industry are responsible for the implementation of 
FDA product quality compliance requirements. Still, many organizations within the 
biotech industry face product recalls for lack of quality compliance and are often fined 
for lack of compliance (Smith & Rupp, 2016). Current research indicates that many 
compliance managers are unable to integrate FDA product quality requirements into their 
quality metrics (Chellener, 2020). 
The theme identified in this study are product quality outcomes, policies and 
procedures and collaborative partnerships. Each of these themes are product quality 
compliance strategies that different quality compliance managers throughout the Western 
region of the United State have identified as strategies used by experienced compliance 
managers to attain full FDA product quality compliance requirements. 
Quality compliance managers can attain FDA product quality compliance through 
several ways. The themes in this study are significant and supports the professional 
practices in the region. The use of strategies such as Demings quality improvement 
strategies can help quality compliance managers attain FDA quality product requirements 
(Deng et al., 2019). Further, Harold et al. (2016) noted that, quality management 
strategies can be used to attain full quality improvement within the biotech industry. 
Implications for Social Change 
According to Haugh and Talwar (2016), positive social change is grounded in the 
elimination of restrictions that prevent or hinders the progress of an organization and, or 
community. Implications for social change for the biotech industry includes jobs and 
availability of much needed drugs for societies. Growth in the biotech industry would 
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improve the overall welfare and living conditions of the public. Also, the education and 
communication of new quality improvement strategies within the organization could 
improve employee morals. According to Oskooee (2017), positive change initiatives can 
increase employee commitment and reduce resistance. Therefore, the communication and 
implementation of quality compliance strategies within the industry can have positive 
effect on the success and growth of the industry resulting from a motivated workforce. 
Recommendations for Action 
Despite numerous quality compliance and good manufacturing publications by 
the FDA, many organizations within the biotech industry have failed to attain required 
FDA product quality compliance requirements. Consequently, more than 70% of 
businesses fail to attain the required quality compliance (Cândido & Santos, 2015). The 
findings of this study may assist current and future business leaders in managing the 
challenges associated with effectively implementing required product quality compliance 
within the biotech industry. Based on the research findings, from this study, the results 
are significant to organizational leaders and quality compliance managers because they 
may benefit from the participants’ experience and the strategies revealed for the 
successful implementation of the strategies used to attain FDA product quality 
compliance requirements. 
Additionally, other manufacturing organizations, besides those in the biotech 
industry could also benefit from implementing the quality implementation strategies 
enunciated in this study. Service organizations in the public and private sectors, profit 
and non-profit organizations may benefit from the findings in this study. The findings 
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from this study may be published as a resource to business leaders through journal 
articles and professional literature. Also, the findings of this study would be shared at 
conferences, seminars and in business courses that I teach. 
Recommendations for Further Research 
The purpose of this study was to help contribute to the gap of the lack of or 
ineffective strategies used by quality compliance managers in the biotech industry to 
attain FDA product quality compliance requirements. I recommend further research on 
this subject. The limitations of the study were the sample size of three biotech 
organizations in the Southern region of the United States not being a representation of all 
the biotech organizations in the United States. Although data saturation was reached in 
this study, extensive research with a broader group of participants is recommended. The 
other limitation of this study was that participants might not have provided honest 
answers to the interview questions that may have effectively represent the strategies used 
within their organization to attain full FDA product quality compliance requirements. 
Reflections 
The Doctor of Business Administration (DBA) program at Walden University 
was challenging, yet astonishingly rewarding. I did not anticipate the amount of time and 
energy required to complete the doctoral study, and as a result, I experienced a few 
setbacks. However, the knowledge obtained throughout this process was fulfilling. I took 
required actions to identify and limit my personal biases within the scope of this study. I 
followed an established interview protocol when conducting interviews with participants 
to mitigate bias. I also conducted member checking by having the participants review a 
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summary of my interpretations of the interview responses to ensure research validity. I 
am also very glad that, in the process of this study, I became familiar with FDA quality 
compliance regime and the strategies used by the biotech industry to attain product 
quality compliance. 
Conclusion 
To attain FDA product quality compliance requirements, organizations must 
create and adopt effective quality compliance strategies throughout all organizational 
product manufacturing processes (Mirza & Ahsan, 2020). Although organizations within 
the biotech industry thrive to attain product quality compliance, many of these 
organizations continuously gets cited for failure to adopt and implement product quality 
compliance requirements. Accordingly, Challener (2020) noted that, a culture of 
compliance is required within the organizations’ manufacturing processes. In this study, I 
used open-ended, semistructured questions to interview five quality compliance managers 
in the Southern region of the United States. Data saturation occurred once information 
became repetitive. From these interviews, three major themes emerged from the collected 
data: product quality outcomes, policies and procedures, and collaborative partnerships. 
The themes which emerged from this study may form the basis upon which effective 
product quality regimes could be attained by product manufacturers in the biotech 
industry. Product quality compliance professionals may apply the findings from this 
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Appendix: Case Study Interview Protocol Checklist 
Pre-Interview 
Interview date: Interview time: 
Interview location: Interview duration estimate: 
Participant pseudonym: Participant code: 
 
Interview documentation and materials 
Receipt of Informed Consent (Yes or 
No): 
Eligibility criteria met (Yes or No): 
Receipt of Permission to Record and 
Transcribe (Yes or No): 
Test Primary and back-up recording 
device 
(Yes or No): 
 
Conduct of interview 
Introductions (Yes or No): Overview of research topic (Yes or 
No): 
Discuss purpose Questions from participant (Yes or 
No): 




Discuss confidentiality Questions from participant (Yes or 
No): 
Discuss right to withdraw Questions from participant (Yes or 
No): 
Discuss benefits Questions from participant (Yes or 
No): 




My observations and actions: a) What leadership strategies do 
you use to embed a culture of quality and 
compliance within your company 
a. Body language  
b. Non-verbal cues  
c. Paraphrasing  
d. Probing questions 
e. Follow-questions 
 b) How does your management team 
formulate and adopt product quality 









 c) How does your organization 
integrate quality compliance strategies into 
your internal and, or external quality 




 d) What total quality 
management processes and tool does your 





 e) How does your organization 
identify the key opportunities for quality 
improvement within your quality and 
compliance processes to assure FDA quality 







Thank participant for contribution Actual interview duration: 
Discuss next steps: Questions from participant (Yes or 
No): 
a. Completion of transcript 
b. Concept of member checking 
c. Set up a date for member checking follow-up 
d. Notification of findings 





Questions from participant (Yes or 
No): 
 
   
 
 
f) What, if any, supply chain management 
technologies do your organization use to address key barriers to 
integrating FDA product quality requirements into your product 
quality metrics? 
 
g) What other information can you provide about the 
strategies used by your organization to apply and integrate 







Member checking follow-up 
Follow-up date: Provide copy of synthesis for each 
question 
Introduce member checking process Questions from participant (Yes or 
No): 
My observations and actions: 
• Additional probing questions 
• Affirm synthesis for each question 
• Ask for further interpretation or additional information 
• Ask what was missed in the initial interview 
a) Synthesis of 1st question 
b) Synthesis of 2nd question 
c) Synthesis of 3rd question 
d) Synthesis of 4th question 
e) Synthesis of 5th question 
f) Synthesis of 6th question 
 
 
